{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:25:01Z","timestamp":1792610701172,"version":"4.5.0"},"reference-count":307,"publisher":"Bentham Science Publishers Ltd.","issue":"38","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>This review encapsulates an extensive variety of substances identified as mutual\nprodrugs or codrugs, wherein two, or sometimes three, biologically active moieties are\nlinked using an assortment of metabolically unstable bridging entities. Following the administration\nof the mutual prodrugs, these undergo a bridge cleavage releasing the active\nmolecules, which then elicit their respective biological effects. In some cases, the released\ndrugs act synergistically, other times the biological activity of only one of the drugs is\nelicited, and in such cases, the accompanying drug serves only as a carrier, which may\nhave an affinity to the desired receptor. The most promising results are commonly observed\nwhen the two released drugs are efficacious at similar concentrations and particularly\nwhen the two drugs are effective against similar diseases. For instance, the best results\nare observed, when two analgesics, two anticancer agents, two drugs for the treatment\nof cardiac conditions, etc., are the substances comprising the codrug. Mutual prodrugs\/\ncodrugs described herein have been reported, primarily since the year 2000, as potential\ndrugs for use against a plethora of diseases including pain, inflammation, cancer,\nbacterial infections, sickle cell anemia, Alzheimer\u2019s disease, and others.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867330666221209102650","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:54:37Z","timestamp":1670824477000},"page":"4283-4339","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Mutual Prodrugs - Codrugs"],"prefix":"10.2174","volume":"30","author":[{"given":"Abraham","family":"Nudelman","sequence":"first","affiliation":[{"name":"Department of Chemistry, Bar Ilan University, Ramat Gan 52900, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.2174\/0929867328666210810124159","volume":"29","author":"Nudelman A.","year":"2022","unstructured":"Nudelman A.; Dimeric drugs. Curr Med Chem 2022,29(16),2751-2845","journal-title":"Curr Med Chem"},{"key":"ref=2","unstructured":"Codrug WikipediaAvailable from:"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/11597630-000000000-00000","volume":"26","author":"M\u00fcller-Schiffmann A.","year":"2012","unstructured":"M\u00fcller-Schiffmann A.; Sticht H.; Korth C.; Hybrid Compounds. BioDrugs 2012,26(1),21-31","journal-title":"BioDrugs"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/17460441.2016.1187597","volume":"11","author":"Parkes A.L.","year":"2016","unstructured":"Parkes A.L.; Yule I.A.; Hybrid antibiotics \u2013 clinical progress and novel designs. Expert Opin Drug Discov 2016,11(7),665-680","journal-title":"Expert Opin Drug Discov"},{"key":"ref=5","doi-asserted-by":"publisher","DOI":"10.1107\/S1600536809047941","volume":"65","author":"Asghar A.","year":"2009","unstructured":"Asghar A.; Iqbal M.S.; Tahir M.N.; Mutual prodrug of cephazolin and benzydamin: 3-[(1-benzyl-1H-indazol-3-yl)- oxy]-N,N-dimethylpropan-1-aminium 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl] methyl}-8-oxo-7-[(1H-tetrazol-1-yl)acetamido]-5-thia-1-azabicyclo-[4.2.0] octane-2-carbo-xyl-ate (be. Acta Crystallogr Sect E Struct Rep Online 2009,65(12)","journal-title":"Acta Crystallogr Sect E Struct Rep Online"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.4155\/fmc.14.25","volume":"6","author":"Rosini M.","year":"2014","unstructured":"Rosini M.; Polypharmacology: the rise of multitarget drugs over combination therapies. Future Med Chem 2014,6(5),485-487","journal-title":"Future Med Chem"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1021\/acsinfecdis.9b00019","volume":"5","author":"Cheng A.V.","year":"2019","unstructured":"Cheng A.V.; Wuest W.M.; Signed, sealed, delivered: Conjugate and prodrug strategies as targeted delivery vectors for antibiotics. ACS Infect Dis 2019,5(6),816-828","journal-title":"ACS Infect Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1021\/jm7009364","volume":"51","author":"Cavalli A.","year":"2008","unstructured":"Cavalli A.; Bolognesi M.L.; Minarini A.; Rosini M.; Tumiatti V.; Recanatini M.; Melchiorre C.; Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008,51(3),347-372","journal-title":"J Med Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"240146","DOI":"10.1155\/2012\/240146","volume":"2012","author":"Cacciatore I.","year":"2012","unstructured":"Cacciatore I.; Baldassarre L.; Fornasari E.; Mollica A.; Pinnen F.; Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems. Oxid Med Cell Longev 2012,2012,240146","journal-title":"Oxid Med Cell Longev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1021\/acs.chemrev.8b00138","volume":"119","author":"Savelieff M.G.","year":"2019","unstructured":"Savelieff M.G.; Nam G.; Kang J.; Lee H.J.; Lee M.; Lim M.H.; Development of multifunctional molecules as potential therapeutic candidates for Alzheimer\u2019s disease, Parkinson\u2019s disease, and amyotrophic lateral sclerosis in the last decade. Chem Rev 2019,119(2),1221-1322","journal-title":"Chem Rev"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/molecules13010046","volume":"13","author":"Di Stefano A.","year":"2008","unstructured":"Di Stefano A.; Sozio P.; Cerasa L.; Antiparkinson prodrugs. Molecules 2008,13(1),46-68","journal-title":"Molecules"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ejmech.2017.12.029","volume":"144","author":"Ghawanmeh A.A.","year":"2018","unstructured":"Ghawanmeh A.A.; Chong K.F.; Sarkar S.M.; Bakar M.A.; Othaman R.; Khalid R.M.; Colchicine prodrugs and codrugs: Chemistry and bioactivities. Eur J Med Chem 2018,144,229-242","journal-title":"Eur J Med Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.3390\/molecules26092601","volume":"26","author":"Szumilak M.","year":"2021","unstructured":"Szumilak M.; Wiktorowska-Owczarek A.; Stanczak A.; Hybrid drugs - a strategy for overcoming anticancer drug resistance? Molecules 2021,26(9),2601","journal-title":"Molecules"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e00077","DOI":"10.1128\/CMR.00077-17","volume":"31","author":"Domalaon R.","year":"2018","unstructured":"Domalaon R.; Idowu T.; Zhanel G.G.; Schweizer F.; Antibiotic hybrids: the next generation of agents and adjuvants against gram-negative pathogens? Clin Microbiol Rev 2018,31(2),e00077-e000717","journal-title":"Clin Microbiol Rev"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.3390\/molecules25071543","volume":"25","author":"Jubeh B.","year":"2020","unstructured":"Jubeh B.; Breijyeh Z.; Karaman R.; Antibacterial prodrugs to overcome bacterial resistance. Molecules 2020,25(7),1543","journal-title":"Molecules"},{"key":"ref=16","first-page":"1960","volume":"4","author":"Dweib K.","year":"2015","unstructured":"Dweib K.; Diclofenac codrugs and prodrugs-three decades of design. World J Pharm Pharm Sci 2015,4(7),1960-1982","journal-title":"World J Pharm Pharm Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"111805","DOI":"10.1016\/j.ejmech.2019.111805","volume":"185","author":"Bai R.","year":"2020","unstructured":"Bai R.; Jie X.; Yao C.; Xie Y.; Discovery of small-molecule candidates against inflammatory bowel disease. Eur J Med Chem 2020,185,111805","journal-title":"Eur J Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"112200","DOI":"10.1016\/j.ejmech.2020.112200","volume":"192","author":"Willetts S.","year":"2020","unstructured":"Willetts S.; Foley D.W.; True or false? Challenges and recent highlights in the development of aspirin prodrugs. Eur J Med Chem 2020,192,112200","journal-title":"Eur J Med Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3906\/kim-1706-58","volume":"42","author":"Mohsin N.A.","year":"2018","unstructured":"Mohsin N.A.; Ahmad M.; Hybrid organic molecules as antiinflammatory agents; a review of structural features and biological activity. Turk J Chem 2018,42(1),1-20","journal-title":"Turk J Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2174\/1874104501711010146","volume":"11","author":"Shah K.","year":"2017","unstructured":"Shah K.; Gupta J.K.; Chauhan N.S.; Upmanyu N.; Shrivastava S.K.; Mishra P.; Prodrugs of NSAIDs. Open Med Chem J 2017,11(1),146-195","journal-title":"Open Med Chem J"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"632","DOI":"10.4103\/0250-474X.78535","volume":"5","author":"Velingkar V.S.","year":"2010","unstructured":"Velingkar V.S.; Jain D.R.; Ahire D.C.; Spacer\/linker based synthesis and biological evaluation of mutual prodrugs as antiinflammatory agents. Indian J Pharm Sci 2010,5(72),632-636","journal-title":"Indian J Pharm Sci"},{"key":"ref=22","first-page":"111","volume":"1","author":"Pratyusha L.","year":"2014","unstructured":"Pratyusha L.; Kavitha M.; Mounika M.; Fatima L.; Prodrugs of NSAIDS\u202f An approach to mitigate gastric irritation. Ann Drug Dis Biomed Res 2014,1(2),111-126","journal-title":"Ann Drug Dis Biomed Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0968-0896(00)00261-3","volume":"9","author":"Matsumoto H.","year":"2001","unstructured":"Matsumoto H.; Matsuda T.; Nakata S.; Mitoguchi T.; Kimura T.; Hayashi Y.; Kiso Y.; Synthesis and biological evaluation of prodrug-type anti-HIV agents: ester conjugates of carboxylic acid-containing dipeptide HIV protease inhibitors and a reverse transcriptase inhibitor. Bioorg Med Chem 2001,9(2),417-430","journal-title":"Bioorg Med Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ejmech.2018.03.007","volume":"150","author":"de Castro S.","year":"2018","unstructured":"de Castro S.; Camarasa M.J.; Polypharmacology in HIV inhibition: can a drug with simultaneous action against two relevant targets be an alternative to combination therapy? Eur J Med Chem 2018,150,206-227","journal-title":"Eur J Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.2174\/138161209789058183","volume":"15","author":"Walsh J.","year":"2009","unstructured":"Walsh J.; Bell A.; Hybrid drugs for malaria. Curr Pharm Des 2009,15(25),2970-2985","journal-title":"Curr Pharm Des"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.3390\/molecules24193604","volume":"24","author":"Peter S.","year":"2019","unstructured":"Peter S.; Aderibigbe B.A.; Ferrocene-based compounds with antimalaria\/anticancer activity. Molecules 2019,24(19),3604","journal-title":"Molecules"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1517\/17460441.2016.1135125","volume":"11","author":"B\u00e9rub\u00e9 G.","year":"2016","unstructured":"B\u00e9rub\u00e9 G.; An overview of molecular hybrids in drug discovery. Expert Opin Drug Discov 2016,11(3),281-305","journal-title":"Expert Opin Drug Discov"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"111653","DOI":"10.1016\/j.ejmech.2019.111653","volume":"182","author":"Hodon J.","year":"2019","unstructured":"Hodon J.; Borkova L.; Pokorny J.; Kazakova A.; Urban M.; Design and synthesis of pentacyclic triterpene conjugates and their use in medicinal research. Eur J Med Chem 2019,182,111653","journal-title":"Eur J Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ejmech.2017.03.005","volume":"131","author":"Zhou M.","year":"2017","unstructured":"Zhou M.; Zhang R.H.; Wang M.; Xu G.B.; Liao S.G.; Prodrugs of triterpenoids and their derivatives. Eur J Med Chem 2017,131,222-236","journal-title":"Eur J Med Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3390\/molecules13030616","volume":"13","author":"Chung M.","year":"2008","unstructured":"Chung M.; Ferreira E.; Santos J.; Giarolla J.; Rando D.; Almeida A.; Bosquesi P.; Menegon R.; Blau L.; Prodrugs for the treatment of neglected diseases. Molecules 2008,13(3),616-677","journal-title":"Molecules"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1080\/17425247.2016.1187598","volume":"13","author":"Aljuffali I.A.","year":"2016","unstructured":"Aljuffali I.A.; Lin C.F.; Chen C.H.; Fang J.Y.; The codrug approach for facilitating drug delivery and bioactivity. Expert Opin Drug Deliv 2016,13(9),1311-1325","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ejps.2010.09.014","volume":"41","author":"Das N.","year":"2010","unstructured":"Das N.; Dhanawat M.; Dash B.; Nagarwal R.C.; Shrivastava S.K.; Codrug: An efficient approach for drug optimization. Eur J Pharm Sci 2010,41(5),571-588","journal-title":"Eur J Pharm Sci"},{"key":"ref=33","first-page":"719","volume":"2","author":"Ohlan M.J.S.","year":"2011","unstructured":"Ohlan M.J.S.; Nanda S.; Pathak D.P.; Mutual Prodrugs- A Swot Analysis. Int J Pharm Sci Res 2011,2,719-729","journal-title":"Int J Pharm Sci Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1021\/jm058225d","volume":"48","author":"Morphy R.","year":"2005","unstructured":"Morphy R.; Rankovic Z.; Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005,48(21),6523-6543","journal-title":"J Med Chem"},{"key":"ref=35","first-page":"277","volume":"3","author":"Dubey S.V.","year":"2014","unstructured":"Dubey S.V.; Valecha V.; Prodrugs: A review. World J Pharm Res 2014,3(7),277-297","journal-title":"World J Pharm Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.3390\/ijms19041104","volume":"19","year":"2018","unstructured":"Pawe\u0142czyk, A.; Sowa-Kasprzak, K.; Olender, D.; Zaprutko, L. Molecular consortia-various structural and synthetic concepts for more effective therapeutics synthesis. Int J Mol Sci 2018,19(4),1104","journal-title":"Int J Mol Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"127514","DOI":"10.1016\/j.bmcl.2020.127514","volume":"30","author":"Sampath Kumar H.M.","year":"2020","unstructured":"Sampath Kumar H.M.; Herrmann L.; Tsogoeva S.B.; Structural hybridization as a facile approach to new drug candidates. Bioorg Med Chem Lett 2020,30(23),127514","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejmech.2018.03.057","volume":"151","author":"Choudhary S.","year":"2018","unstructured":"Choudhary S.; Singh P.K.; Verma H.; Singh H.; Silakari O.; Success stories of natural product-based hybrid molecules for multi-factorial diseases. Eur J Med Chem 2018,151,62-97","journal-title":"Eur J Med Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2174\/156802661708170126200430","volume":"17","author":"Scotti L.","year":"2017","unstructured":"Scotti L.; Mendonca-Junior F.; Scotti M.; Hybrid compounds as multitarget agents in medicinal chemistry \u2013 Part I. Curr Top Med Chem 2017,17(8),843-844","journal-title":"Curr Top Med Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2174\/138955709787847930","volume":"9","author":"Serafin A.","year":"2009","unstructured":"Serafin A.; Sta\u0144czak, A. Different concepts of drug delivery in disease entities. Mini Rev Med Chem 2009,9(4),481-497","journal-title":"Mini Rev Med Chem"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1021\/jm00314a009","volume":"10","author":"Cambanis A.","year":"1967","unstructured":"Cambanis A.; The I.; Potential anticancer agents. II. Urethan-type nitrogen mustards of some natural sex hormones. J Med Chem 1967,10(2),172-174","journal-title":"J Med Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1021\/acs.inorgchem.0c03299","volume":"60","author":"Lee V.E.Y.","year":"2021","unstructured":"Lee V.E.Y.; Lim Z.C.; Chew S.L.; Ang W.H.; Strategy for traceless codrug delivery with platinum (IV) prodrug complexes using self-immolative linkers. Inorg Chem 2021,60(3),1823-1831","journal-title":"Inorg Chem"},{"key":"ref=43","author":"Askelof A.E.E.","year":"1946","unstructured":"Askelof A.E.E.; Heterocyclic sulphonamido azo compounds. 1946"},{"key":"ref=44","first-page":"278","volume":"23","author":"Doraswamy K.R.","year":"1946","unstructured":"Doraswamy K.R.; Guha P.C.; Studies in sulphanilamides. Part VI. N1- and N4-substituted sulphanilamides-azo-dyes derived from sulphathiazole and sulphapyridine. J Indian Chem Soc 1946,23,278","journal-title":"J Indian Chem Soc"},{"key":"ref=45","first-page":"114","volume":"50","author":"Malatesta P.","year":"1960","unstructured":"Malatesta P.; Sulfamethazine-5-aminosalicylic acid. Ann Chim (Rome) 1960,50,114","journal-title":"Ann Chim (Rome)"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1365-2125.1989.tb03563.x","volume":"28","author":"Williams F.M.","year":"1989","unstructured":"Williams F.M.; Moore U.; Seymour R.A.; Mutch E.M.; Nicholson E.; Wright P.; Wynne H.; Blain P.G.; Rawlins M.D.; Benorylate hydrolysis by human plasma and human liver. Br J Clin Pharmacol 1989,28(6),703-708","journal-title":"Br J Clin Pharmacol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1021\/jm00314a009","volume":"10","author":"Niculescu-Duvaz I.","year":"1967","unstructured":"Niculescu-Duvaz I.; Cambanis A.; T\u00e1rn\u00e1uceanu E.; Cambanis A.; Potential anticancer agents. II. Urethan-type nitrogen mustards of some natural sex hormones. J Med Chem 1967,10(2),172-174","journal-title":"J Med Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1021\/jm7012453","volume":"51","author":"Nudelman A.","year":"2008","unstructured":"Nudelman A.; Gil-Ad I.; Shpaisman N.; Terasenko I.; Ron H.; Savitsky K.; Geffen Y.; Weizman A.; Rephaeli A.; A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects. J Med Chem 2008,51(9),2858-2862","journal-title":"J Med Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1358\/dof.2012.037.09.1873628","volume":"37","author":"Gras J.","year":"2012","unstructured":"Gras J.; Perphenazine 4-aminobutyrate mesylate. Drugs Future 2012,37(9),645-650","journal-title":"Drugs Future"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1021\/jm900143u","volume":"52","author":"Rephaeli A.","year":"2009","unstructured":"Rephaeli A.; Gil-Ad, I.; Aharoni, A.; Tarasenko, I.; Tarasenko, N.; Geffen, Y.; Halbfinger, E.; Nisemblat, Y.; Weizman, A.; Nudelman, A. \u0393-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. J Med Chem 2009,52(9),3010-3017","journal-title":"J Med Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"7356","DOI":"10.1021\/jm8008794","volume":"51","author":"Berkovitch G.","year":"2008","unstructured":"Berkovitch G.; Doron D.; Nudelman A.; Malik Z.; Rephaeli A.; Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity independent and dependent on photoactivation. J Med Chem 2008,51(23),7356-7369","journal-title":"J Med Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"102345","DOI":"10.1016\/j.bcmd.2019.102345","volume":"79","author":"Oseghale A.R.","year":"2019","unstructured":"Oseghale A.R.; Zhu X.; Li B.; Peterson K.R.; Nudelman A.; Rephaeli A.; Xu H.; Pace B.S.; Conjugate prodrug AN-233 induces fetal hemoglobin expression in sickle erythroid progenitors and \u03b2-YAC transgenic mice. Blood Cells Mol Dis 2019,79(July),102345","journal-title":"Blood Cells Mol Dis"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"286","DOI":"10.4103\/0250-474X.26654","volume":"68","author":"Dhaneshwar S.S.","year":"2006","unstructured":"Dhaneshwar S.S.; Bhosle D.; Bharambe S.; Gairola N.; Mutual prodrug concept: Fundamentals and applications. Indian J Pharm Sci 2006,68(3),286-294","journal-title":"Indian J Pharm Sci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/(SICI)1521-4184(19998)332:8<286:AID-ARDP286>3.0.CO;2-9","volume":"332","author":"Xia Z.","year":"1999","unstructured":"Xia Z.; Wiebe L.I.; Miller G.G.; Knaus E.E.; Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2\u2032-deoxyuridine and 2\u20325-difluoro-2\u2032-deoxyuridine as potential dual action anticancer prodrugs. Arch Pharm (Weinheim) 1999,332(8),286-294","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/1098-2299(200007\/08)50:3\/4<379::AID-DDR20>3.0.CO;2-8","volume":"50","author":"Rephaeli A.","year":"2000","unstructured":"Rephaeli A.; Zhuk R.; Nudelman A.; Prodrugs of butyric acid from bench to bedside: Synthetic design, mechanisms of action, and clinical applications. Drug Dev Res 2000,50(3-4),379-391","journal-title":"Drug Dev Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/sj.bjc.6603781","volume":"96","author":"Rephaeli A.","year":"2007","unstructured":"Rephaeli A.; Waks-Yona S.; Nudelman A.; Tarasenko I.; Tarasenko N.; Phillips D.R.; Cutts S.M.; Kessler-Icekson G.; Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity. Br J Cancer 2007,96(11),1667-1674","journal-title":"Br J Cancer"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.bcp.2014.01.023","volume":"88","author":"Tarasenko N.","year":"2014","unstructured":"Tarasenko N.; Cutts S.M.; Phillips D.R.; Berkovitch-Luria G.; Bardugo-Nissim E.; Weitman M.; Nudelman A.; Rephaeli A.; A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo. Biochem Pharmacol 2014,88(2),158-168","journal-title":"Biochem Pharmacol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1002\/jcb.26512","volume":"119","author":"Tarasenko N.","year":"2018","unstructured":"Tarasenko N.; Chekroun-Setti H.; Nudelman A.; Rephaeli A.; Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors. J Cell Biochem 2018,119(4),3417-3428","journal-title":"J Cell Biochem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1021\/jm7009827","volume":"51","author":"Engel D.","year":"2008","unstructured":"Engel D.; Nudelman A.; Tarasenko N.; Levovich I.; Makarovsky I.; Sochotnikov S.; Tarasenko I.; Rephaeli A.; Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties. J Med Chem 2008,51(2),314-323","journal-title":"J Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0223-5234(93)90008-3","volume":"28","author":"Nudelman A.","year":"1993","unstructured":"Nudelman A.; Ben-Ishai Z.; Ruse M.; Schamroth J.; Skin-depigmenting prodrugs of hydroquinone. Eur J Med Chem 1993,28(2),159-164","journal-title":"Eur J Med Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/ardp.19933261112","volume":"326","author":"Nudelman A.","year":"1993","unstructured":"Nudelman A.; Kelner R.; Approaches to mutual prodrugs: calcium-\u03b2-blockers. Arch Pharm (Weinheim) 1993,326(11),907-909","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1039\/C9MD00337A","volume":"10","author":"Blaikie L.","year":"2019","unstructured":"Blaikie L.; Kay G.; Kong Thoo Lin P.; Current and emerging therapeutic targets of Alzheimer\u2019s disease for the design of multi-target directed ligands. MedChemComm 2019,10(12),2052-2072","journal-title":"MedChemComm"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ardp.200900152","volume":"343","author":"Sozio P.","year":"2010","unstructured":"Sozio P.; D\u2019Aurizio E.; Iannitelli A.; Cataldi A.; Zara S.; Cantalamessa F.; Nasuti C.; Di Stefano A.; Ibuprofen and lipoic acid diamides as potential codrugs with neuroprotective activity. Arch Pharm (Weinheim) 2010,343(3),133-142","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.brainres.2011.07.022","volume":"1412","author":"Zara S.","year":"2011","unstructured":"Zara S.; Rapino M.; Sozio P.; Di Stefano A.; Nasuti C.; Cataldi A.; Ibuprofen and lipoic acid codrug 1 control Alzheimer\u2019s disease progression by down-regulating protein kinase C \u03b5-mediated metalloproteinase 2 and 9 levels in \u03b2-amyloid infused Alzheimer\u2019s disease rat model. Brain Res 2011,1412,79-87","journal-title":"Brain Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.freeradbiomed.2010.03.011","volume":"49","author":"Minelli A.","year":"2010","unstructured":"Minelli A.; Conte C.; Prudenzi E.; Cacciatore I.; Cornacchia C.; Taha E.; Pinnen F.; N-Acetyl-L-Methionyl-L-Dopa-Methyl Ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity. Free Radic Biol Med 2010,49(1),31-39","journal-title":"Free Radic Biol Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ejmech.2013.09.011","volume":"69","author":"Lu C.","year":"2013","unstructured":"Lu C.; Kim B.M.; Lee D.; Lee M.H.; Kim J.H.; Pyo H.B.; Chai K.Y.; Synthesis of lipoic acid\u2013peptide conjugates and their effect on collagen and melanogenesis. Eur J Med Chem 2013,69,449-454","journal-title":"Eur J Med Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/cmdc.201200320","volume":"7","author":"Cacciatore I.","year":"2012","unstructured":"Cacciatore I.; Baldassarre L.; Fornasari E.; Cornacchia C.; Di Stefano A.; Sozio P.; Cerasa L.S.; Fontana A.; Fulle S.; Di Filippo E.S.; La Rovere R.M.L.; Pinnen F.; (R)-\u03b1-lipoyl-glycyl-L-prolyl-L-glutamyl dimethyl ester codrug as a multifunctional agent with potential neuroprotective activities. ChemMedChem 2012,7(11),2021-2029","journal-title":"ChemMedChem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1021\/jm101450p","volume":"54","author":"Schiefer I.T.","year":"2011","unstructured":"Schiefer I.T.; Abdul-Hay S.; Wang H.; Vanni M.; Qin Z.; Thatcher G.R.J.; Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates. J Med Chem 2011,54(7),2293-2306","journal-title":"J Med Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1021\/jm5000613","volume":"57","author":"L\u00f3pez-Iglesias B.","year":"2014","unstructured":"L\u00f3pez-Iglesias B.; P\u00e9rez C.; Morales-Garc\u00eda J.A.; Alonso-Gil S.; P\u00e9rez-Castillo A.; Romero A.; L\u00f3pez M.G.; Villarroya M.; Conde S.; Rodr\u00edguez-Franco M.I.; New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer\u2019s disease. J Med Chem 2014,57(9),3773-3785","journal-title":"J Med Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"5776","DOI":"10.1002\/slct.201803672","volume":"4","author":"Girek M.","year":"2019","unstructured":"Girek M.; Szyma\u0144ski P.; Phyto-Tacrine Hybrids as Promising Drugs to Treat Alzheimer\u2019s Disease. ChemistrySelect 2019,4(19),5776-5790","journal-title":"ChemistrySelect"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"112997","DOI":"10.1016\/j.ejmech.2020.112997","volume":"212","author":"Liu Z.","year":"2021","unstructured":"Liu Z.; Zhang B.; Xia S.; Fang L.; Gou S.; ROS-responsive and multifunctional anti-Alzheimer prodrugs: Tacrine-ibuprofen hybrids via a phenyl boronate linker. Eur J Med Chem 2021,212,112997","journal-title":"Eur J Med Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1039\/c0md00256a","volume":"2","author":"Bornstein J.J.","year":"2011","unstructured":"Bornstein J.J.; Eckroat T.J.; Houghton J.L.; Jones C.K.; Green K.D.; Garneau-Tsodikova S.; Tacrine-mefenamic acid hybrids for inhibition of acetylcholinesterase. MedChemComm 2011,2(5),406-412","journal-title":"MedChemComm"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1021\/jm300246n","volume":"55","author":"Chen X.","year":"2012","unstructured":"Chen X.; Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo. J Med Chem 2012,55,5231-5242","journal-title":"J Med Chem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1111\/jphp.12070","volume":"65","author":"Zenger K.","year":"2013","unstructured":"Zenger K.; Chen X.; Decker M.; Kraus B.; In-vitro stability and metabolism of a tacrine\u2013silibinin codrug. J Pharm Pharmacol 2013,65(12),1765-1772","journal-title":"J Pharm Pharmacol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"9967","DOI":"10.1021\/acs.jmedchem.6b01178","volume":"59","author":"Benchekroun M.","year":"2016","unstructured":"Benchekroun M.; Romero A.; Egea J.; Le\u00f3n R.; Michalska P.; Buend\u00eda I.; Jimeno M.L.; Jun D.; Janockova J.; Sepsova V.; Soukup O.; Bautista-Aguilera O.M.; Refouvelet B.; Ouari O.; Marco-Contelles J.; Ismaili L.; The antioxidant additive approach for Alzheimer\u2019s disease therapy: New ferulic (Lipoic) acid plus melatonin modified tacrines as cholinesterases inhibitors, direct antioxidants, and nuclear factor (erythroid-derived 2)-like 2 activators. J Med Chem 2016,59(21),9967-9973","journal-title":"J Med Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1021\/jm050746d","volume":"49","author":"Rodr\u00edguez-Franco M.I.","year":"2006","unstructured":"Rodr\u00edguez-Franco M.I.; Fern\u00e1ndez-Bachiller M.I.; P\u00e9rez C.; Hern\u00e1ndez-Ledesma B.; Bartolom\u00e9 B.; Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J Med Chem 2006,49(2),459-462","journal-title":"J Med Chem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/cmdc.201402409","volume":"10","author":"Benchekroun M.","year":"2015","unstructured":"Benchekroun M.; Bartolini M.; Egea J.; Romero A.; Soriano E.; Pudlo M.; Luzet V.; Andrisano V.; Jimeno M.L.; L\u00f3pez M.G.; Wehle S.; Gharbi T.; Refouvelet B.; de Andr\u00e9s L.; Herrera-Arozamena C.; Monti B.; Bolognesi M.L.; Rodr\u00edguez-Franco M.I.; Decker M.; Marco-Contelles J.; Ismaili L.; Novel tacrine-grafted Ugi adducts as multipotent anti-Alzheimer drugs: a synthetic renewal in tacrine-ferulic acid hybrids. ChemMedChem 2015,10(3),523-539","journal-title":"ChemMedChem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.3390\/molecules18022397","volume":"18","author":"Spilovska K.","year":"2013","unstructured":"Spilovska K.; Korabecny J.; Kral J.; Horova A.; Musilek K.; Soukup O.; Drtinova L.; Gazova Z.; Siposova K.; Kuca K.; 7-Methoxytacrine-adamantylamine heterodimers as cholinesterase inhibitors in Alzheimer\u2019s disease treatment--synthesis, biological evaluation and molecular modeling studies. Molecules 2013,18(2),2397-2418","journal-title":"Molecules"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"6089","DOI":"10.1016\/j.bmc.2014.08.035","volume":"22","author":"Lan J.S.","year":"2014","unstructured":"Lan J.S.; Xie S.S.; Li S.Y.; Pan L.F.; Wang X.B.; Kong L.Y.; Design, synthesis and evaluation of novel tacrine-(\u03b2-carboline) hybrids as multifunctional agents for the treatment of Alzheimer\u2019s disease. Bioorg Med Chem 2014,22(21),6089-6104","journal-title":"Bioorg Med Chem"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"5685","DOI":"10.1021\/jm070859s","volume":"50","author":"Elsinghorst P.W.","year":"2007","unstructured":"Elsinghorst P.W.; Cieslik J.S.; Mohr K.; Tr\u00e4nkle C.; G\u00fctschow M.; First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor. J Med Chem 2007,50(23),5685-5695","journal-title":"J Med Chem"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"989S","DOI":"10.1093\/jn\/131.3.989S","volume":"131","author":"Yeh Y.Y.","year":"2001","unstructured":"Yeh Y.Y.; Liu L.; Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies. J Nutr 2001,131(3),989S-993S","journal-title":"J Nutr"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/cbdd.12633","volume":"87","author":"Keri R.S.","year":"2016","unstructured":"Keri R.S.; Quintanova C.; Chaves S.; Silva D.F.; Cardoso S.M.; Santos M.A.; New tacrine hybrids with natural-based cysteine derivatives as multitargeted drugs for potential treatment of Alzheimer\u2019s Disease. Chem Biol Drug Des 2016,87(1),101-111","journal-title":"Chem Biol Drug Des"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1021\/jm900859q","volume":"52","author":"Camps P.","year":"2009","unstructured":"Camps P.; Formosa X.; Galdeano C.; Mu\u00f1oz-Torrero D.; Ram\u00edrez L.; G\u00f3mez E.; Isambert N.; Lavilla R.; Badia A.; Clos M.V.; Bartolini M.; Mancini F.; Andrisano V.; Arce M.P.; Rodr\u00edguez-Franco M.I.; Huertas \u00d3.; Dafni T.; Luque F.J.; Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and \u03b2-amyloid-directed anti-Alzheimer compounds. J Med Chem 2009,52(17),5365-5379","journal-title":"J Med Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ejmech.2018.02.023","volume":"148","author":"Hiremathad A.","year":"2018","unstructured":"Hiremathad A.; Keri R.S.; Esteves A.R.; Cardoso S.M.; Chaves S.; Santos M.A.; Novel Tacrine-Hydroxyphenyl-benzimidazole hybrids as potential multitarget drug candidates for Alzheimer\u2019s disease. Eur J Med Chem 2018,148,255-267","journal-title":"Eur J Med Chem"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/14756366.2019.1689237","volume":"35","author":"Fancellu G.","year":"2020","unstructured":"Fancellu G.; Chand K.; Tom\u00e1s D.; Orlandini E.; Piemontese L.; Silva D.F.; Cardoso S.M.; Chaves S.; Santos M.A.; Novel tacrine\u2013benzofuran hybrids as potential multi-target drug candidates for the treatment of Alzheimer\u2019s Disease. J Enzyme Inhib Med Chem 2020,35(1),211-226","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1039\/C5MD00236B","volume":"6","author":"Quintanova C.","year":"2015","unstructured":"Quintanova C.; Keri R.S.; Marques S.M.; G-Fernandes, M.; Cardoso, S.M.; Lu\u00edsa Serralheiro, M.; Am\u00e9lia Santos, M. Design, synthesis and bioevaluation of tacrine hybrids with cinnamate and cinnamylidene acetate derivatives as potential anti-Alzheimer drugs. MedChemComm 2015,6(11),1969-1977","journal-title":"MedChemComm"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1021\/acsmedchemlett.7b00463","volume":"9","author":"Jiang X.Y.","year":"2018","unstructured":"Jiang X.Y.; Chen T.K.; Zhou J.T.; He S.Y.; Yang H.Y.; Chen Y.; Qu W.; Feng F.; Sun H.P.; Dual GSK-3\u03b2\/AChE inhibitors as a new strategy for multitargeting anti-Alzheimer\u2019s disease drug discovery. ACS Med Chem Lett 2018,9(3),171-176","journal-title":"ACS Med Chem Lett"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejmech.2015.01.058","volume":"93","author":"Xie S.S.","year":"2015","unstructured":"Xie S.S.; Lan J.S.; Wang X.B.; Jiang N.; Dong G.; Li Z.R.; Wang K.D.G.; Guo P.P.; Kong L.Y.; Multifunctional tacrine\u2013trolox hybrids for the treatment of Alzheimer\u2019s disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties. Eur J Med Chem 2015,93,42-50","journal-title":"Eur J Med Chem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"8985","DOI":"10.1021\/acs.jmedchem.5b01325","volume":"58","author":"Nepovimova E.","year":"2015","unstructured":"Nepovimova E.; Korabecny J.; Dolezal R.; Babkova K.; Ondrejicek A.; Jun D.; Sepsova V.; Horova A.; Hrabinova M.; Soukup O.; Bukum N.; Jost P.; Muckova L.; Kassa J.; Malinak D.; Andrs M.; Kuca K.; Tacrine\u2013Trolox Hybrids: A novel class of centrally active, nonhepatotoxic multi-target-directed ligands exerting anticholinesterase and antioxidant activities with low in vivo toxicity. J Med Chem 2015,58(22),8985-9003","journal-title":"J Med Chem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.7164\/antibiotics.33.1183","volume":"33","author":"Baltzer B.","year":"1980","unstructured":"Baltzer B.; Binderup E.; Daehne W.V.; Godtfredsen W.O.; Hansen K.; Nielsen B.; Sorensen H.; Vangedal S.; Mutual pro-drugs of. BETA.-lactam antibiotics and. BETA.-lactamase inhibitors. J Antibiot (Tokyo) 1980,33(10),1183-1192","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/14732300020300S103","volume":"30","author":"Adam D.","year":"2002","unstructured":"Adam D.; Beta-lactam\/beta-lactamase inhibitor combinations in empiric management of pediatric infections. J Int Med Res 2002,30(Suppl. 1),10-19","journal-title":"J Int Med Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1128\/AAC.48.2.477-483.2004","volume":"48","author":"Stone G.W.","year":"2004","unstructured":"Stone G.W.; Zhang Q.; Castillo R.; Doppalapudi V.R.; Bueno A.R.; Lee J.Y.; Li Q.; Sergeeva M.; Khambatta G.; Georgopapadakou N.H.; Mechanism of action of NB2001 and NB2030, novel antibacterial agents activated by \u03b2-lactamases. Antimicrob Agents Chemother 2004,48(2),477-483","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/ja.2008.80","volume":"61","author":"Long D.D.","year":"2008","unstructured":"Long D.D.; Aggen J.B.; Chinn J.; Choi S-K.; Christensen B.G.; Fatheree P.R.; Green D.; Hegde S.S.; Judice J.K.; Kaniga K.; Krause K.M.; Leadbetter M.; Linsell M.S.; Marquess D.G.; Moran E.J.; Nodwell M.B.; Pace J.L.; Trapp S.G.; Turner. S.D. Exploring the positional attachment of glycopeptide\/beta-lactam heterodimers. J Antibiot 2008,61(10),603-614","journal-title":"J Antibiot"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1128\/AAC.06274-11","volume":"56","author":"Tyrrell K.L.","year":"2012","unstructured":"Tyrrell K.L.; Citron D.M.; Warren Y.A.; Goldstein E.J.C.; In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species. Antimicrob Agents Chemother 2012,56(4),2194-2197","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1128\/AAC.33.6.944","volume":"33","author":"Jones R.N.","year":"1989","unstructured":"Jones R.N.; Barry A.L.; Thornsberry C.; Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime. Antimicrob Agents Chemother 1989,33(6),944-950","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1517\/13543784.6.10.1479","volume":"6","author":"Bryskier A.","year":"1997","unstructured":"Bryskier A.; Dual \u03b2-lactam-fluoroquinolone compounds: a novel approach to antibacterial treatment. Expert Opin Investig Drugs 1997,6(10),1479-1499","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"9677","DOI":"10.1021\/ja503911p","volume":"136","author":"Zheng T.","year":"2014","unstructured":"Zheng T.; Nolan E.M.; Enterobactin-mediated delivery of \u03b2-lactam antibiotics enhances antibacterial activity against pathogenic Escherichia coli. J Am Chem Soc 2014,136(27),9677-9691","journal-title":"J Am Chem Soc"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.3390\/molecules24193601","volume":"24","author":"Alven S.","year":"2019","unstructured":"Alven S.; Aderibigbe B.; Combination therapy strategies for the treatment of malaria. Molecules 2019,24(19),3601","journal-title":"Molecules"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1016\/j.bmcl.2007.04.054","volume":"17","author":"Walsh J.J.","year":"2007","unstructured":"Walsh J.J.; Coughlan D.; Heneghan N.; Gaynor C.; Bell A.; A novel artemisinin\u2013quinine hybrid with potent antimalarial activity. Bioorg Med Chem Lett 2007,17(13),3599-3602","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1016\/j.bmc.2003.07.004","volume":"11","author":"Chung M.C.","year":"2003","unstructured":"Chung M.C.; G\u00fcido R.V.C.; Martinelli T.F.; Gon\u00e7alves M.F.; Polli M.C.; Botelho K.C.A.; Varanda E.A.; Colli W.; Miranda M.T.M.; Ferreira E.I.; Synthesis and in vitro evaluation of potential antichagasic hydroxymethylnitrofurazone (NFOH-121): a new nitrofurazone prodrug. Bioorg Med Chem 2003,11(22),4779-4783","journal-title":"Bioorg Med Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.bmc.2018.11.018","volume":"27","author":"Karag\u00f6z A.\u00c7.","year":"2019","unstructured":"Karag\u00f6z A.\u00c7.; Leidenberger M.; Hahn F.; Hampel F.; Friedrich O.; Marschall M.; Kappes B.; Tsogoeva S.B.; Synthesis of new betulinic acid\/betulin-derived dimers and hybrids with potent antimalarial and antiviral activities. Bioorg Med Chem 2019,27(1),110-115","journal-title":"Bioorg Med Chem"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1021\/mp800007x","volume":"5","author":"Chavain N.","year":"2008","unstructured":"Chavain N.; Vezin H.; Dive D.; Touati N.; Paul J.F.; Buisine E.; Biot C.; Investigation of the redox behavior of ferroquine, a new antimalarial. Mol Pharm 2008,5(5),710-716","journal-title":"Mol Pharm"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1051\/parasite\/2011183207","volume":"18","author":"Biot C.","year":"2011","unstructured":"Biot C.; Nosten F.; Fraisse L.; Ter-Minassian D.; Khalife J.; Dive D.; The antimalarial ferroquine: from bench to clinic. Parasite 2011,18(3),207-214","journal-title":"Parasite"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1055\/s-0031-1296211","volume":"61","author":"N-Da D.","year":"2011","unstructured":"N-Da D.; Breytenbach J.; Smith P.; Lategan C.; Synthesis and in vitro antiplasmodial activityof quinoline-ferrocene esters. Arzneimittelforschung 2011,61(6),358-365","journal-title":"Arzneimittelforschung"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"13066","DOI":"10.1002\/anie.201907224","volume":"58","year":"2019","unstructured":"\u00c7apc\u0131 A.; Lorion, M.M.; Wang, H.; Simon, N.; Leidenberger, M.; Borges Silva, M.C.; Moreira, D.R.M.; Zhu, Y.; Meng, Y.; Chen, J.Y.; Lee, Y.M.; Friedrich, O.; Kappes, B.; Wang, J.; Ackermann, L.; Tsogoeva, S.B. Artemisinin\u2013(Iso)quinoline hybrids by C\u2212H activation and click chemistry: combating multidrug-resistant malaria. Angew Chem Int Ed 2019,58(37),13066-13079","journal-title":"Angew Chem Int Ed"},{"key":"ref=106","author":"Kumar E.H.","year":"2017","unstructured":"Kumar E.H.; Subramanyam S.K.; Thamizhvanan K.; Synthesis, characterization, antimicrobial evaluation and forced degradation studies of mutual amide prodrug of moxifloxacin and isoniazid. Int J Pharm Chem Sci 2017","journal-title":"Int J Pharm Chem Sci"},{"key":"ref=107","first-page":"521","volume":"4","author":"Husain A.","year":"2015","unstructured":"Husain A.; Studies on a mutual prodrug of nalidixic acid. Int J Green Herb Chem 2015,4,521-526","journal-title":"Int J Green Herb Chem"},{"key":"ref=108","first-page":"32","volume":"11","author":"Husain A.","year":"2020","unstructured":"Husain A.; Design, synthesis, and antibacterial study of new gatifloxacin-antioxidants as mutual prodrugs. J Biochem Technol 2020,11(1),32-36","journal-title":"J Biochem Technol"},{"key":"ref=109","first-page":"89","volume":"1819","author":"Hussein A.K.","year":"2016","unstructured":"Hussein A.K.; Nasser N.H.; Abdulsada A.H.; Hasan S.A.; Design, Synthesis, and characterization of a novel Ciprofloxacin-Antioxidant mutual prodrugs. Der Pharma Chem 2016,1819,89-92","journal-title":"Der Pharma Chem"},{"key":"ref=110","first-page":"3061","volume":"10","author":"Hasan S.","year":"2018","unstructured":"Hasan S.; A Synthesis and antibacterial evaluation of new ofloxacin-chalcone derivatives conjugates as possible mutual prodrugs. J Pharm Sci Res 2018,10(12),3061-3065","journal-title":"J Pharm Sci Res"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1021\/jm900028n","volume":"52","author":"Pokrovskaya V.","year":"2009","unstructured":"Pokrovskaya V.; Belakhov V.; Hainrichson M.; Yaron S.; Baasov T.; Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics. J Med Chem 2009,52(8),2243-2254","journal-title":"J Med Chem"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2174\/138527208784577402","volume":"12","author":"Jampilek J.","year":"2008","unstructured":"Jampilek J.; Reckova Z.; Imramovsky A.; Raich I.; Vinsova J.; Dohnal J.; Study of stability of new mutual prodrugs with antimycobacterial activity. Curr Org Chem 2008,12(8),667-674","journal-title":"Curr Org Chem"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"12","DOI":"10.13040\/IJPSR.0975-8232.9(11).4709-15","volume":"6","author":"Gangarde D.","year":"2014","unstructured":"Gangarde D.; Karande R.; Synthesis, characterization and evaluation of Schiff\u2019s base mutual prodrugs of naproxen. Int J Pharm Sci Res 2014,6,12-25","journal-title":"Int J Pharm Sci Res"},{"key":"ref=114","first-page":"43","volume":"4","author":"Husain S.A.K.A.","year":"2015","unstructured":"Husain S.A.K.A.; Ahmad A.; Studies on an amide based mutual prodrug: synthesis and evaluation. J Biomed Pharm Res 2015,4,43-46","journal-title":"J Biomed Pharm Res"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3998\/ark.5550190.0008.112","volume":"2007","author":"Rawat J.","year":"2007","unstructured":"Rawat J.; Jain P.K.; Ravichandran V.; Agrawal R.K.; Synthesis and evaluation of mutual prodrugs of isoniazid, p-amino salicylic acid and ethambutol. ARKIVOC 2007,2007(1),105-118","journal-title":"ARKIVOC"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejps.2013.12.001","volume":"53","author":"Kr\u00e1tk\u00fd M.","year":"2014","unstructured":"Kr\u00e1tk\u00fd M.; Vin\u0161ov\u00e1 J.; Novotn\u00e1 E.; Stola\u0159\u00edkov\u00e1, J. Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase. Eur J Pharm Sci 2014,53(1),1-9","journal-title":"Eur J Pharm Sci"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1039\/C9OB00680J","volume":"17","author":"Pastor A.","year":"2019","unstructured":"Pastor A.; Machelart A.; Li X.; Willand N.; Baulard A.; Brodin P.; Gref R.; Desma\u00eble D.; A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation. Org Biomol Chem 2019,17(20),5129-5137","journal-title":"Org Biomol Chem"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.bmcl.2004.01.007","volume":"14","author":"Sriram D.","year":"2004","unstructured":"Sriram D.; Yogeeswari P.; Srichakravarthy N.; Bal T.R.; Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV\/AIDS. Bioorg Med Chem Lett 2004,14(5),1085-1087","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"e0120937","DOI":"10.1371\/journal.pone.0120937","volume":"10","author":"Cacciatore I.","year":"2015","unstructured":"Cacciatore I.; Di Giulio M.; Fornasari E.; Di Stefano A.; Cerasa L.S.; Marinelli L.; Turkez H.; Di Campli E.; Di Bartolomeo S.; Robuffo I.; Cellini L.; Carvacrol codrugs: a new approach in the antimicrobial plan. PLoS One 2015,10(4),e0120937","journal-title":"PLoS One"},{"key":"ref=120","first-page":"22","volume":"22","author":"Abdulhadi S.L.","year":"2013","unstructured":"Abdulhadi S.L.; Qasir A.J.; Razzak N.A.A.; Synthesis of new Conjugates of some NSAIDs with Sulfonamide as possible mutual prodrugs using tyrosine spacer for colon targeted drug delivery. Iraqi J Pharm Sci 2013,22(2),22-29","journal-title":"Iraqi J Pharm Sci"},{"key":"ref=121","first-page":"2067","volume":"3","author":"Hussain A.","year":"2014","unstructured":"Hussain A.; Parashar P.; Shrivastava A.A.K.; Synthesis, characterization and release studies of mutual prodrugs of norfloxacin and trimethoprim with aspirin for colon release. World J Pharm Pharm Sci 2014,3(6),2067-2074","journal-title":"World J Pharm Pharm Sci"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"127549","DOI":"10.1016\/j.bmcl.2020.127549","volume":"30","author":"Ansari M.F.","year":"2020","unstructured":"Ansari M.F.; Inam A.; Ahmad K.; Fatima S.; Agarwal S.M.; Azam A.; Synthesis of metronidazole based thiazolidinone analogs as promising antiamoebic agents. Bioorg Med Chem Lett 2020,30(23),127549","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1021\/acs.jmedchem.8b00218","volume":"61","author":"Liu R.","year":"2018","unstructured":"Liu R.; Miller P.A.; Vakulenko S.B.; Stewart N.K.; Boggess W.C.; Miller M.J.; A synthetic dual drug sideromycin induces gram-negative bacteria to commit suicide with a gram-positive antibiotic. J Med Chem 2018,61(9),3845-3854","journal-title":"J Med Chem"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1773-2247(09)50003-2","volume":"19","author":"Dhaneshwar S.S.","year":"2009","unstructured":"Dhaneshwar S.S.; Patil D.; Mengi S.; Mulay G.; Lahane J.; Diacerein mutual prodrug for osteoarthritis: synthesis, in vitro kinetic studies and preliminary pharmacological screening. J Drug Deliv Sci Technol 2009,19(1),25-29","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1773-2247(09)50087-1","volume":"19","author":"Dhaneshwar S.S.","year":"2009","unstructured":"Dhaneshwar S.S.; Patil D.; Mengi S.; Mulay G.; Lahane J.; Evaluation of the chondroprotective effect of mutual prodrug of diacerein in monosodium iodoacetate-induced osteoarthritis in Wistar rats. J Drug Deliv Sci Technol 2009,19(6),425-430","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bmcl.2012.11.016","volume":"23","author":"Dhaneshwar S.","year":"2013","unstructured":"Dhaneshwar S.; Patel V.; Patil D.; Meena G.; Studies on synthesis, stability, release and pharmacodynamic profile of a novel diacerein-thymol prodrug. Bioorg Med Chem Lett 2013,23(1),55-61","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"e00417","DOI":"10.1002\/prp2.417","volume":"6","author":"Hasan M.","year":"2018","unstructured":"Hasan M.; Leak R.K.; Stratford R.E.; Zlotos D.P.; Witt-Enderby P.A.; Drug conjugates-an emerging approach to treat breast cancer. Pharmacol Res Perspect 2018,6(4),e00417","journal-title":"Pharmacol Res Perspect"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/jcc.26192","volume":"41","author":"Pakdel M.","year":"2020","unstructured":"Pakdel M.; Raissi H.; Hosseini S.T.; Evaluation the synergistic antitumor effect of methotrexate\u2013camptothecin codelivery prodrug from self-assembly process to acid-catalyzed both drugs release: A comprehensive theoretical study. J Comput Chem 2020,41(16),1486-1496","journal-title":"J Comput Chem"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1039\/C8RA08794F","volume":"9","author":"Assali M.","year":"2019","unstructured":"Assali M.; Kittana N.; Qasem S.A.; Adas R.; Saleh D.; Arar A.; Zohud O.; Combretastatin A4-camptothecin micelles as combination therapy for effective anticancer activity. RSC Advances 2019,9(2),1055-1061","journal-title":"RSC Advances"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/biomedicines4030015","volume":"4","author":"Keely N.","year":"2016","unstructured":"Keely N.; Carr M.; Yassin B.; Ana G.; Lloyd D.; Zisterer D.; Meegan M.; Design, synthesis and biochemical evaluation of novel selective estrogen receptor ligand conjugates incorporating an endoxifen-combretastatin hybrid scaffold. Biomedicines 2016,4(3),15","journal-title":"Biomedicines"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/molecules22091440","volume":"22","author":"Kelly P.","year":"2017","unstructured":"Kelly P.; Keely N.; Bright S.; Yassin B.; Ana G.; Fayne D.; Zisterer D.; Meegan M.; Novel selective estrogen receptor ligand conjugates incorporating endoxifen-combretastatin and cyclofenil-combretastatin hybrid scaffolds: Synthesis and biochemical evaluation. Molecules 2017,22(9),1440","journal-title":"Molecules"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1860-5397-2-13","volume":"2","author":"Bombuwala K.","year":"2006","unstructured":"Bombuwala K.; Colchitaxel, a coupled compound made from microtubule inhibitors colchicine and paclitaxel. Beilstein J Org Chem 2006,2,1-10","journal-title":"Beilstein J Org Chem"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1021\/jo052677g","volume":"71","author":"Danieli B.","year":"2006","unstructured":"Danieli B.; Giardini A.; Lesma G.; Passarella D.; Peretto B.; Sacchetti A.; Silvani A.; Pratesi G.; Zunino F.; Thiocolchicine-podophyllotoxin conjugates: dynamic libraries based on disulfide exchange reaction. J Org Chem 2006,71(7),2848-2853","journal-title":"J Org Chem"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1016\/j.bmc.2013.03.049","volume":"21","author":"Zhang X.","year":"2013","unstructured":"Zhang X.; Zhang J.; Tong L.; Luo Y.; Su M.; Zang Y.; Li J.; Lu W.; Chen Y.; The discovery of colchicine-SAHA hybrids as a new class of antitumor agents. Bioorg Med Chem 2013,21(11),3240-3244","journal-title":"Bioorg Med Chem"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"10391","DOI":"10.1021\/jm501112q","volume":"57","author":"Vilanova C.","year":"2014","unstructured":"Vilanova C.; D\u00edaz-Oltra S.; Murga J.; Falomir E.; Carda M.; Redondo-Horcajo M.; D\u00edaz J.F.; Barasoain I.; Marco J.A.; Design and synthesis of pironetin analogue\/colchicine hybrids and study of their cytotoxic activity and mechanisms of interaction with tubulin. J Med Chem 2014,57(24),10391-10403","journal-title":"J Med Chem"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"8987","DOI":"10.1021\/jo049953w","volume":"69","author":"Bagnato J.D.","year":"2004","unstructured":"Bagnato J.D.; Eilers A.L.; Horton R.A.; Grissom C.B.; Synthesis and characterization of a cobalamin-colchicine conjugate as a novel tumor-targeted cytotoxin. J Org Chem 2004,69(26),8987-8996","journal-title":"J Org Chem"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1351\/pac200375020187","volume":"75","author":"Baraldi P.G.","year":"2003","unstructured":"Baraldi P.G.; Tabrizi M.A.; Preti D.; Fruttarolo F.; Avitabile B.; Bovero A.; Pavani G.; del Carretero M.C.N.; Romagnoli R.; DNA minor-groove binders. Design, synthesis and biological evaluation of ligands structurally related to CC-1065, distamycin, and anthramycin. Pure Appl Chem 2003,75(2-3),187-194","journal-title":"Pure Appl Chem"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1021\/jm011113b","volume":"45","author":"Baraldi P.G.","year":"2002","unstructured":"Baraldi P.G.; Romagnoli R.; Guadix A.E.; Pineda de las Infantas M.J.; Gallo M.A.; Espinosa A.; Martinez A.; Bingham J.P.; Hartley J.A.; Design, synthesis, and biological activity of hybrid compounds between uramustine and DNA minor groove binder distamycin A. J Med Chem 2002,45(17),3630-3638","journal-title":"J Med Chem"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3998\/ark.5550190.0007.704","volume":"2006","author":"Baraldi P.G.","year":"2005","unstructured":"Baraldi P.G.; Zaid A.N.; Preti D.; Fruttarolo F.; Tabrizi M.A.; Iaconinoto A.; Pavani M.G.; Carrion M.D.; Cara C.L.; Romagnoli R.; Hybrid molecules based on distamycin A as potential antitumor agents. ARKIVOC 2005,2006(7),20-34","journal-title":"ARKIVOC"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bmc.2006.07.004","volume":"15","author":"Baraldi P.G.","year":"2007","unstructured":"Baraldi P.G.; Preti D.; Fruttarolo F.; Tabrizi M.A.; Romagnoli R.; Hybrid molecules between distamycin A and active moieties of antitumor agents. Bioorg Med Chem 2007,15(1),17-35","journal-title":"Bioorg Med Chem"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1021\/ml100302t","volume":"2","author":"Chegaev K.","year":"2011","unstructured":"Chegaev K.; Riganti C.; Lazzarato L.; Rolando B.; Guglielmo S.; Campia I.; Fruttero R.; Bosia A.; Gasco A.; Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity. ACS Med Chem Lett 2011,2(7),494-497","journal-title":"ACS Med Chem Lett"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.bmcl.2018.12.017","volume":"29","author":"Liu W.","year":"2019","unstructured":"Liu W.; Liang L.; Zhao L.; Tan H.; Wu J.; Qin Q.; Gou X.; Sun X.; Synthesis and characterization of a photoresponsive doxorubicin\/combretastatin A4 hybrid prodrug. Bioorg Med Chem Lett 2019,29(3),487-490","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1021\/jm030352r","volume":"47","author":"Burke P.J.","year":"2004","unstructured":"Burke P.J.; Koch T.H.; Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells. J Med Chem 2004,47(5),1193-1206","journal-title":"J Med Chem"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.1021\/jm049496b","volume":"47","author":"Burke P.J.","year":"2004","unstructured":"Burke P.J.; Kalet B.T.; Koch T.H.; Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells. J Med Chem 2004,47(26),6509-6518","journal-title":"J Med Chem"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ejmech.2016.05.068","volume":"121","author":"Jiang Y.","year":"2016","unstructured":"Jiang Y.; Li X.; Hou J.; Huang Y.; Jia Y.; Zou M.; Zhang J.; Wang X.; Xu W.; Zhang Y.; Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent. Eur J Med Chem 2016,121,649-657","journal-title":"Eur J Med Chem"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejmech.2017.11.074","volume":"143","author":"Jiang Y.","year":"2018","unstructured":"Jiang Y.; Li X.; Hou J.; Huang Y.; Wang X.; Jia Y.; Wang Q.; Xu W.; Zhang J.; Zhang Y.; Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy. Eur J Med Chem 2018,143,334-347","journal-title":"Eur J Med Chem"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"9083","DOI":"10.1021\/jo971076p","volume":"62","author":"Menger F.M.","year":"1997","unstructured":"Menger F.M.; Rourk M.J.; Synthesis and reactivity of 5-fluorouracil\/cytarabine mutual prodrugs. J Org Chem 1997,62(26),9083-9088","journal-title":"J Org Chem"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.3390\/molecules15042114","volume":"15","author":"Zhou W.M.","year":"2010","unstructured":"Zhou W.M.; He R.R.; Ye J.T.; Zhang N.; Liu D.Y.; Synthesis and biological evaluation of new 5-fluorouracil-substituted ampelopsin derivatives. Molecules 2010,15(4),2114-2123","journal-title":"Molecules"},{"key":"ref=149","volume":"25","author":"Mustafa Y.F.","year":"2016","unstructured":"Mustafa Y.F.; Al-omari N.A.; Design, synthesis and kinetic study of coumarin-based mutual prodrug of 5-fluorouracil and dichloroacetic acid. Iraqi J Pharm Sci 2016,25(1)","journal-title":"Iraqi J Pharm Sci"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"97","DOI":"10.37358\/RC.20.12.8390","volume":"71","author":"Mustafa Y.F.","year":"2021","unstructured":"Mustafa Y.F.; Oglah M.K.; Bashir M.K.; Synthesis and Kinetic Study of Novel Coumarin- Based Mutual Prodrug of 5-fluorouracil and 5-ethynyluracil. Revista de Chimie 2021,71(12),97-108","journal-title":"Revista de Chimie"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"482","DOI":"10.5530\/srp.2020.3.61","volume":"11","author":"Mustafa Y.F.","year":"2020","unstructured":"Mustafa Y.F.; Oglah M.K.; Bashir M.K.; Conjugation of sinapic acid analogues with 5-fluorouracil: Synthesis, preliminary cytotoxicity, and release study. Syst Rev Pharm 2020,11(3),482-489","journal-title":"Syst Rev Pharm"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ejps.2012.05.017","volume":"47","author":"Berkovitch-Luria G.","year":"2012","unstructured":"Berkovitch-Luria G.; Yakobovitch S.; Weitman M.; Nudelman A.; Rozic G.; Rephaeli A.; Malik Z.; A multifunctional 5-aminolevulinic acid derivative induces erythroid differentiation of K562 human erythroleukemic cells. Eur J Pharm Sci 2012,47(1),206-214","journal-title":"Eur J Pharm Sci"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejmech.2018.09.008","volume":"158","author":"Qin Q.P.","year":"2018","unstructured":"Qin Q.P.; Wang S.L.; Tan M.X.; Wang Z.F.; Luo D.M.; Zou B.Q.; Liu Y.C.; Yao P.F.; Liang H.; Novel tacrine platinum(II) complexes display high anticancer activity via inhibition of telomerase activity, dysfunction of mitochondria, and activation of the p53 signaling pathway. Eur J Med Chem 2018,158(3),106-122","journal-title":"Eur J Med Chem"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1039\/c3cc38957j","volume":"49","author":"Ding S.","year":"2013","unstructured":"Ding S.; Qiao X.; Kucera G.L.; Bierbach U.; Design of a platinum\u2013acridine\u2013endoxifen conjugate targeted at hormone-dependent breast cancer. Chem Commun (Camb) 2013,49(24),2415-2417","journal-title":"Chem Commun (Camb)"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1677\/ERC-09-0113","volume":"16","author":"Van Themsche C.","year":"2009","unstructured":"Van Themsche C.; Parent S.; Leblanc V.; Desc\u00f4teaux C.; Simard A.M.; B\u00e9rub\u00e9 G.; Asselin E.; VP-128, a novel oestradiol-platinum(II) hybrid with selective anti-tumour activity towards hormone-dependent breast cancer cells in vivo. Endocr Relat Cancer 2009,16(4),1185-1195","journal-title":"Endocr Relat Cancer"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bioorg.2004.06.009","volume":"33","author":"Perron V.","year":"2005","unstructured":"Perron V.; Rabouin D.; Asselin E.; Parent S.; C-Gaudreault, R.; B\u00e9rub\u00e9, G. Synthesis of 17\u03b2-estradiol-linked platinum(II) complexes and their cytocidal activity on estrogen-dependent and -independent breast tumor cells. Bioorg Chem 2005,33(1),1-15","journal-title":"Bioorg Chem"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1080\/00914037.2018.1455681","volume":"68","author":"Diainabo K.J.","year":"2019","unstructured":"Diainabo K.J.; Neuse E.W.; Chen C.T.; Lynne Van Zyl R.; Design and synthesis of polysapartamide co-drugs of platinum and methotrexate as anticancer agents. Int J Polym Mater 2019,68(8),452-462","journal-title":"Int J Polym Mater"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1021\/acs.inorgchem.0c00445","volume":"59","author":"Babu T.","year":"2020","unstructured":"Babu T.; Sarkar A.; Karmakar S.; Schmidt C.; Gibson D.; Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules. Inorg Chem 2020,59(7),5182-5193","journal-title":"Inorg Chem"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.chembiol.2004.03.024","volume":"11","author":"Barnes K.R.","year":"2004","unstructured":"Barnes K.R.; Kutikov A.; Lippard S.J.; Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol 2004,11(4),557-564","journal-title":"Chem Biol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"22199","DOI":"10.1073\/pnas.0912276106","volume":"106","author":"Dhar S.","year":"2009","unstructured":"Dhar S.; Lippard S.J.; Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc Natl Acad Sci USA 2009,106(52),22199-22204","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1021\/ja0432618","volume":"127","author":"Ang W.H.","year":"2005","unstructured":"Ang W.H.; Khalaila I.; Allardyce C.S.; Juillerat-Jeanneret L.; Dyson P.J.; Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J Am Chem Soc 2005,127(5),1382-1383","journal-title":"J Am Chem Soc"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"18218","DOI":"10.1002\/anie.201910014","volume":"58","author":"Yempala T.","year":"2019","unstructured":"Yempala T.; Babu T.; Karmakar S.; Nemirovski A.; Ishan M.; Gandin V.; Gibson D.; Expanding the arsenal of PtIV anticancer agents: Multi-action PtIV anticancer agents with bioactive ligands possessing a hydroxy functional group. Angew Chem Int Ed 2019,58(50),18218-18223","journal-title":"Angew Chem Int Ed"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1021\/acs.bioconjchem.6b00353","volume":"27","author":"Huang X.","year":"2016","unstructured":"Huang X.; Huang R.; Gou S.; Wang Z.; Liao Z.; Wang H.; Combretastatin A-4 analogue: A dual-targeting and tubulin inhibitor containing antitumor Pt(IV) moiety with a unique mode of action. Bioconjug Chem 2016,27(9),2132-2148","journal-title":"Bioconjug Chem"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"11076","DOI":"10.1021\/acs.inorgchem.9b01583","volume":"58","author":"Yao H.","year":"2019","unstructured":"Yao H.; Xu Z.; Li C.; Tse M.K.; Tong Z.; Zhu G.; Synthesis and cytotoxic study of a platinum(IV) anticancer prodrug with selectivity toward luteinizing hormone-releasing hormone (LHRH) receptor-positive cancer cells. Inorg Chem 2019,58(16),11076-11084","journal-title":"Inorg Chem"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1021\/jm990540a","volume":"43","author":"Nudelman A.","year":"2000","unstructured":"Nudelman A.; Rephaeli A.; Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity. J Med Chem 2000,43(15),2962-2966","journal-title":"J Med Chem"},{"key":"ref=166","first-page":"903","volume":"1","author":"Mann K.K.","year":"2003","unstructured":"Mann K.K.; Rephaeli A.; Colosimo A.L.; Diaz Z.; Nudelman A.; Levovich I.; Jing Y.; Waxman S.; Miller W.H.; Jr. A retinoid\/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis. Mol Cancer Res 2003,1(12),903-912","journal-title":"Mol Cancer Res"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1021\/jm8001839","volume":"51","author":"Gediya L.K.","year":"2008","unstructured":"Gediya L.K.; Khandelwal A.; Patel J.; Belosay A.; Sabnis G.; Mehta J.; Purushottamachar P.; Njar V.C.O.; Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro. J Med Chem 2008,51(13),3895-3904","journal-title":"J Med Chem"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.bmcl.2019.03.015","volume":"29","author":"Sansom G.N.","year":"2019","unstructured":"Sansom G.N.; Kirk N.S.; Guise C.P.; Anderson R.F.; Smaill J.B.; Patterson A.V.; Kelso M.J.; Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study. Bioorg Med Chem Lett 2019,29(10),1215-1219","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1016\/S0960-894X(02)00784-9","volume":"12","author":"Vrudhula V.M.","year":"2002","unstructured":"Vrudhula V.M.; MacMaster J.F.; Li Z.; Kerr D.E.; Senter P.D.; Reductively activated disulfide prodrugs of paclitaxel. Bioorg Med Chem Lett 2002,12(24),3591-3594","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1016\/j.bmc.2016.09.033","volume":"24","author":"Jiang Y.","year":"2016","unstructured":"Jiang Y.; Hou J.; Li X.; Huang Y.; Wang X.; Wu J.; Zhang J.; Xu W.; Zhang Y.; Discovery of a novel chimeric ubenimex\u2013gemcitabine with potent oral antitumor activity. Bioorg Med Chem 2016,24(22),5787-5795","journal-title":"Bioorg Med Chem"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/j.bmcl.2019.06.060","volume":"29","author":"Paidakula S.","year":"2019","unstructured":"Paidakula S.; Nerella S.; Vadde R.; Kamal A.; Kankala S.; Design and synthesis of 4\u03b2-Acetamidobenzofuranone-podophyllotoxin hybrids and their anti-cancer evaluation. Bioorg Med Chem Lett 2019,29(16),2153-2156","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1021\/acsmedchemlett.9b00378","volume":"11","author":"Garces A.E.","year":"2020","unstructured":"Garces A.E.; Al-Hayali M.; Lee J.B.; Li J.; Gershkovich P.; Bradshaw T.D.; Stocks M.J.; Codrug approach for the potential treatment of EML4-ALK positive lung cancer. ACS Med Chem Lett 2020,11(3),316-321","journal-title":"ACS Med Chem Lett"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1248\/cpb.c19-00520","volume":"67","author":"Omran Z.","year":"2019","unstructured":"Omran Z.; Alarja M.; Abdalla A.N.; Ibrahim M.M.; Hossain M.A.; Chen L.; Liu Y.; Wang Q.; Design, synthesis, and in vitro biological evaluation of 14-hydroxytylophorine-dichloroacetate co-drugs as antiproliferative agents. Chem Pharm Bull (Tokyo) 2019,67(11),1208-1210","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=174","first-page":"2318","volume":"37","author":"Berger A.S.","year":"1996","unstructured":"Berger A.S.; Cheng C.K.; Pearson P.A.; Ashton P.; Crooks P.A.; Cynkowski T.; Cynkowska G.; Jaffe G.J.; Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1996,37(11),2318-2325","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1021\/jm010511b","volume":"45","author":"Macky T.A.","year":"2002","unstructured":"Macky T.A.; Oelkers C.; Rix U.; Heredia M.L.; K\u00fcnzel E.; Wimberly M.; Rohrer B.; Crosson C.E.; Rohr J.; Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate. J Med Chem 2002,45(5),1122-1127","journal-title":"J Med Chem"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.bmcl.2017.01.025","volume":"27","author":"Idippily N.D.","year":"2017","unstructured":"Idippily N.D.; Gan C.; Orefice P.; Peterson J.; Su B.; Synthesis of Vorinostat and cholesterol conjugate to enhance the cancer cell uptake selectivity. Bioorg Med Chem Lett 2017,27(4),816-820","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=177","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0960-894X(96)00004-2","volume":"6","author":"Brown G.R.","year":"1996","unstructured":"Brown G.R.; Clarke D.S.; Faull A.W.; Foubister A.J.; Smithers M.J.; Design of dual-acting thromboxane antagonist-synthase inhibitors by a mutual prodrug approach. Bioorg Med Chem Lett 1996,6(3),273-278","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1016\/j.bmcl.2016.08.058","volume":"26","author":"Gao H.","year":"2016","unstructured":"Gao H.; Yang X.; Gu X.; Zhu Y.Z.; Synthesis and biological evaluation of the codrug of Leonurine and Aspirin as cardioprotective agents. Bioorg Med Chem Lett 2016,26(19),4650-4654","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejmech.2012.09.016","volume":"57","author":"Yang X.Z.","year":"2012","unstructured":"Yang X.Z.; Yang W.H.; Xu Y.G.; Diao X.J.; He G.W.; Gong G.Q.; Synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing a cleavable moiety with anti-platelet activity. Eur J Med Chem 2012,57,21-28","journal-title":"Eur J Med Chem"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"608221","DOI":"10.3389\/fphar.2020.608221","volume":"11","author":"Zhang J.","year":"2021","unstructured":"Zhang J.; Jiang M.; Zhao H.; Han L.; Jin Y.; Chen W.; Wang J.; Zhang Z.; Peng C.; Synthesis of paeonol-ozagrel conjugate: Structure characterization and in vivo anti-ischemic stroke potential. Front Pharmacol 2021,11(February),608221","journal-title":"Front Pharmacol"},{"key":"ref=181","first-page":"1","volume":"5","author":"Asnani A.J.","year":"2018","unstructured":"Asnani A.J.; Patari S.; Chaple D.R.; Pratyush K.; Synthesis and evaluation of mutual prodrugs from clopidogrel analogues and salicylic acid. Eur J Biomed Pharm Sci 2018,5,1-6","journal-title":"Eur J Biomed Pharm Sci"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3109\/03639045.2011.560155","volume":"37","author":"Abu Zanat F.Z.","year":"2011","unstructured":"Abu Zanat F.Z.; Qandil A.M.; Tashtoush B.M.; A promising codrug of nicotinic acid and ibuprofen for managing dyslipidemia. I: Synthesis and in vitro evaluation. Drug Dev Ind Pharm 2011,37(9),1090-1099","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejps.2011.03.012","volume":"43","author":"Qandil A.M.","year":"2011","unstructured":"Qandil A.M.; Rezigue M.M.; Tashtoush B.M.; Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. Eur J Pharm Sci 2011,43(3),99-108","journal-title":"Eur J Pharm Sci"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"105731","DOI":"10.1016\/j.ejps.2021.105731","volume":"159","author":"Mascarello A.","year":"2021","unstructured":"Mascarello A.; Azevedo H.; Ferreira Junior, M.A.; Ishikawa E.E.; Guimar\u00e3es C.R.W.; Design, synthesis and antihypertensive evaluation of novel codrugs with combined angiotensin type 1 receptor antagonism and neprilysin inhibition. Eur J Pharm Sci 2021,159,105731","journal-title":"Eur J Pharm Sci"},{"key":"ref=185","first-page":"173","volume":"27","author":"Baidya M.","year":"2011","unstructured":"Baidya M.; Das A.K.; Synthesis and hydrolysis kinetic study of few co-drugs of propranolol and other antihypertensive drugs. Orient J Chem 2011,27(1),173-178","journal-title":"Orient J Chem"},{"key":"ref=186","first-page":"740","volume":"4","author":"Budhalakoti L.","year":"2015","unstructured":"Budhalakoti L.; Suneela D.; Chopade S.; Kamble H.; Exploring thioester chemistry in mutual prodrug design for combination antihypertensive therapy. World J Pharm Res 2015,4,740-767","journal-title":"World J Pharm Res"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"9641","DOI":"10.1021\/jo201358e","volume":"76","author":"Kennedy D.A.","year":"2011","unstructured":"Kennedy D.A.; Vembu N.; Fronczek F.R.; Devocelle M.; Synthesis of mutual azo prodrugs of anti-inflammatory agents and peptides facilitated by \u03b1-aminoisobutyric acid. J Org Chem 2011,76(23),9641-9647","journal-title":"J Org Chem"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2147\/DDDT.S48636","volume":"7","author":"Jilani J.","year":"2013","unstructured":"Jilani J.; Shomaf M.; Alzoubi K.H.; Synthesis and evaluation of mutual azo prodrug of 5-aminosalicylic acid linked to 2-phenylbenzoxazole-2-yl-5-acetic acid in ulcerative colitis. Drug Des Devel Ther 2013,7,691-698","journal-title":"Drug Des Devel Ther"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1021\/acs.molpharmaceut.6b00294","volume":"13","author":"Kim W.","year":"2016","unstructured":"Kim W.; Nam J.; Lee S.; Jeong S.; Jung Y.; 5-Aminosalicylic acid azo-linked to procainamide acts as an anticolitic mutual prodrug via additive inhibition of nuclear factor kappaB. Mol Pharm 2016,13(6),2126-2135","journal-title":"Mol Pharm"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1021\/acs.molpharmaceut.9b00872","volume":"17","author":"Jeong S.","year":"2020","unstructured":"Jeong S.; Lee H.; Kim S.; Ju S.; Kim W.; Cho H.; Kim H.Y.; Heo G.; Im, E.; Yoo, J.W.; Yoon, I.S.; Jung, Y. 5-Aminosalicylic acid azo-coupled with a GPR109A agonist is a colon-targeted anticolitic codrug with a reduced risk of skin toxicity. Mol Pharm 2020,17(1),167-179","journal-title":"Mol Pharm"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1021\/acs.molpharmaceut.0c01228","volume":"18","author":"Lee H.","year":"2021","unstructured":"Lee H.; Park S.; Ju S.; Kim S.; Yoo J.W.; Yoon I.S.; Min D.S.; Jung Y.; Preparation and evaluation of colon-targeted prodrugs of the microbial metabolite 3-indolepropionic acid as an anticolitic agent. Mol Pharm 2021,18(4),1730-1741","journal-title":"Mol Pharm"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"35","DOI":"10.7897\/2277-4572.02212","volume":"2","author":"Walsangikar S.","year":"2013","unstructured":"Walsangikar S.; Bhatia N.; Synthesis and evaluation of mutual prodrug of aspirin and chlorzoxazone. J Pharmaceut Sci Innovat 2013,2(2),35-40","journal-title":"J Pharmaceut Sci Innovat"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"36","DOI":"10.22270\/ajprd.v6i6.452","volume":"6","author":"Andhale G.","year":"2018","unstructured":"Andhale G.; Chemical hydrolysis, in silico physicochemical properties and in-vivo pharmacological evaluation of antidiabetic and antihypertensive codrugs. Asian J Pharm Res Devel 2018,6,36-43","journal-title":"Asian J Pharm Res Devel"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.molstruc.2018.06.030","volume":"1171","author":"Vyas B.","year":"2018","unstructured":"Vyas B.; Choudhary S.; Singh P.K.; Singh A.; Singh M.; Verma H.; Singh H.; Bahadur R.; Singh B.; Silakari O.; Molecular dynamics\/quantum mechanics guided designing of natural products based prodrugs of Epalrestat. J Mol Struct 2018,1171,556-563","journal-title":"J Mol Struct"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"104556","DOI":"10.1016\/j.bioorg.2020.104556","volume":"108","author":"Choudhary S.","year":"2021","unstructured":"Choudhary S.; Kumar M.; Silakari O.; QM\/MM analysis, synthesis and biological evaluation of epalrestat based mutual-prodrugs for diabetic neuropathy and nephropathy. Bioorg Chem 2021,108,104556","journal-title":"Bioorg Chem"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1586\/17469872.3.2.221","volume":"3","author":"Strasinger C.L.","year":"2008","unstructured":"Strasinger C.L.; Scheff N.N.; Stinchcomb A.L.; Prodrugs and codrugs as strategies for improving percutaneous absorption. Expert Rev Dermatol 2008,3(2),221-233","journal-title":"Expert Rev Dermatol"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"794","DOI":"10.2174\/138161208784007653","volume":"14","author":"Lau W.","year":"2008","unstructured":"Lau W.; White A.; Gallagher S.; Donaldson M.; McNaughton G.; Heard C.; Scope and limitations of the co-drug approach to topical drug delivery. Curr Pharm Des 2008,14(8),794-802","journal-title":"Curr Pharm Des"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jconrel.2006.04.003","volume":"113","author":"Kiptoo P.K.","year":"2006","unstructured":"Kiptoo P.K.; Hamad M.O.; Crooks P.A.; Stinchcomb A.L.; Enhancement of transdermal delivery of 6-\u03b2-naltrexol via a codrug linked to hydroxybupropion. J Control Release 2006,113(2),137-145","journal-title":"J Control Release"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ejps.2008.01.006","volume":"33","author":"Kiptoo P.K.","year":"2008","unstructured":"Kiptoo P.K.; Paudel K.S.; Hammell D.C.; Hamad M.O.; Crooks P.A.; Stinchcomb A.L.; In vivo evaluation of a transdermal codrug of 6-\u03b2-naltrexol linked to hydroxybupropion in hairless guinea pigs. Eur J Pharm Sci 2008,33(4-5),371-379","journal-title":"Eur J Pharm Sci"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijpharm.2004.05.008","volume":"280","author":"Abdulmajed K.","year":"2004","unstructured":"Abdulmajed K.; Heard C.M.; Topical delivery of retinyl ascorbate co-drug. Int J Pharm 2004,280(1-2),113-124","journal-title":"Int J Pharm"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1159\/000093980","volume":"19","author":"Abdulmajed K.","year":"2006","unstructured":"Abdulmajed K.; McGuigan C.; Heard C.M.; Topical delivery of retinyl ascorbate co-drug. 5. In vitro degradation studies. Skin Pharmacol Physiol 2006,19(5),248-258","journal-title":"Skin Pharmacol Physiol"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0169-409X(95)00010-5","volume":"16","author":"J\u00e4rvinen K.","year":"1995","unstructured":"J\u00e4rvinen K.; J\u00e4rvinen T.; Urtti A.; Ocular absorption following topical delivery. Adv Drug Deliv Rev 1995,16(1),3-19","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1016\/j.bmcl.2005.05.128","volume":"15","author":"Cynkowska G.","year":"2005","unstructured":"Cynkowska G.; Cynkowski T.; Al-Ghananeem A.A.; Guo H.; Ashton P.; Crooks P.A.; Novel antiglaucoma prodrugs and codrugs of ethacrynic acid. Bioorg Med Chem Lett 2005,15(15),3524-3527","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/14756360500220319","volume":"20","author":"Howard-Sparks M.","year":"2005","unstructured":"Howard-Sparks M.; Al-Ghananeem A.M.; Pearson A.P.; Crooks P.A.; Evaluation of O3\u03b1-, O21-Di-(N1-methyloxy-carbonyl-2, 4-dioxo-5-fluoropyrimidinyl)17\u03b1-hydroxy-5\u03b2-pregnan-20-one as a novel potential antiangiogenic codrug. J Enzyme Inhib Med Chem 2005,20(5),417-428","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/03639040601134108","volume":"33","author":"Howard-Sparks M.","year":"2007","unstructured":"Howard-Sparks M.; Al-Ghananeem A.M.; Crooks P.A.; Pearson A.P.; A novel chemical delivery system comprising an ocular sustained release formulation of a 3\u03b1 17\u03b1 21-trihydroxy-5\u03b2-pregnan-20-one-BIS- 5-flourouracil codrug. Drug Dev Ind Pharm 2007,33(6),677-682","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/12030373","volume":"12","author":"Al-Ghananeem A.","year":"2007","unstructured":"Al-Ghananeem A.; Crooks P.; Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery. Molecules 2007,12(3),373-388","journal-title":"Molecules"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1136\/bjo.2003.039917","volume":"88","author":"Cardillo J.A.","year":"2004","unstructured":"Cardillo J.A.; Farah M.E.; Mitre J.; Morales P.H.; Costa R.A.; Melo L.A.; Kuppermann B.; Jorge R.; Ashton P.; An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. Br J Ophthalmol 2004,88(9),1201-1205","journal-title":"Br J Ophthalmol"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s11172-020-2798-3","volume":"69","author":"Lavrushkina E.A.","year":"2020","unstructured":"Lavrushkina E.A.; Shibilev V.M.; Zefirov N.A.; Shevtsova E.F.; Shevtsov P.N.; Kuznetsov S.A.; Zefirova O.N.; \u201cTriple\u201d mutual prodrug based on 2-methoxyestradiol: synthesis and biotesting in vitro. Russ Chem Bull 2020,69(3),558-562","journal-title":"Russ Chem Bull"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.2147\/DDDT.S88543","volume":"9","author":"Jung Y.","year":"2015","unstructured":"Jung Y.; Lee S.; Lee Y.; Kim W.; Nam J.; Jeong S.; Yoo J-W.; Kim M-S.; Moon H.R.; Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-\u03baB, an anti-inflammatory target. Drug Des Devel Ther 2015,9,4227-4237","journal-title":"Drug Des Devel Ther"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1002\/jps.23469","volume":"102","author":"Ghosh P.","year":"2013","unstructured":"Ghosh P.; Pinninti R.R.; Hammell D.C.; Paudel K.S.; Stinchcomb A.L.; Pharmaceutics, drug delivery and pharmaceutical technology development of a codrug approach for sustained drug delivery across microneedle-treated skin. J Pharm Sci 2013,102(5),1458-1467","journal-title":"J Pharm Sci"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s11095-013-1147-8","volume":"31","author":"Ghosh P.","year":"2014","unstructured":"Ghosh P.; Lee D.; Kim K.B.; Stinchcomb A.L.; Optimization of naltrexone diclofenac codrugs for sustained drug delivery across microneedle-treated skin. Pharm Res 2014,31(1),148-159","journal-title":"Pharm Res"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijpharm.2015.03.001","volume":"485","author":"Laserra S.","year":"2015","unstructured":"Laserra S.; Basit A.; Sozio P.; Marinelli L.; Fornasari E.; Cacciatore I.; Ciulla M.; T\u00fcrkez H.; Geyikoglu F.; Di Stefano A.; Solid lipid nanoparticles loaded with lipoyl\u2013memantine codrug: Preparation and characterization. Int J Pharm 2015,485(1-2),183-191","journal-title":"Int J Pharm"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/jps.24053","volume":"103","author":"Thomas S.","year":"2014","unstructured":"Thomas S.; Vieira C.S.; Hass M.A.; Lopes L.B.; Stability, cutaneous delivery, and antioxidant potential of a lipoic acid and \u03b1-tocopherol codrug incorporated in microemulsions. J Pharm Sci 2014,103(8),2530-2538","journal-title":"J Pharm Sci"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejpb.2017.01.016","volume":"114","author":"Hsieh P.W.","year":"2017","unstructured":"Hsieh P.W.; Hung C.F.; Lin C.H.; Huang C.W.; Fang J.Y.; Anti-melasma codrug of retinoic acid assists cutaneous absorption with attenuated skin irritation. Eur J Pharm Biopharm 2017,114,154-163","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.antiviral.2012.10.003","volume":"96","author":"Yang Q.","year":"2012","unstructured":"Yang Q.; Zhao X.; Zang L.; Fang X.; Zhao J.; Yang X.; Wang Q.; Zheng L.; Chang J.; Anti-hepatitis B virus activities of \u03b1-DDB\u2013FNC, a novel nucleoside\u2013biphenyldicar-boxylate compound in cells and ducks, and its anti-immunological liver injury effect in mice. Antiviral Res 2012,96(3),333-339","journal-title":"Antiviral Res"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1254\/jphs.13230FP","volume":"126","author":"Yang Q.","year":"2014","unstructured":"Yang Q.; Zhao X.; Yu W.; He W.; Fang X.; Zang L.; Wan N.; Wang Q.; Zheng L.; Chang J.; Anti-hepatitis B virus activity of \u03b1-DDB-FNCG, a novel nucleoside-biphenyldicarboxylate compound in vitro and in vivo. J Pharmacol Sci 2014,126(3),208-215","journal-title":"J Pharmacol Sci"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.ejmech.2005.07.006","volume":"40","author":"Sriram D.","year":"2005","unstructured":"Sriram D.; Yogeeswari P.; Gopal G.; Synthesis, anti-HIV and antitubercular activities of lamivudine prodrugs. Eur J Med Chem 2005,40(12),1373-1376","journal-title":"Eur J Med Chem"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10529-004-7335-1","volume":"27","author":"Sun X.F.","year":"2005","unstructured":"Sun X.F.; Wu Q.; Wang N.; Cai Y.; Lin X.F.; Novel mutual pro-drugs of 2-3-dideoxyinosine with 3-octade-cyloxy-propane-1,2-diol by straightforward enzymatic regioselective synthesis in acetone. Biotechnol Lett 2005,27(2),113-117","journal-title":"Biotechnol Lett"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1021\/acsmedchemlett.0c00375","volume":"11","author":"Rossi M.","year":"2020","unstructured":"Rossi M.; Petralla, S.; Protti, M.; Baiula, M.; Kobrlova, T.; Soukup, O.; Spampinato, S.M.; Mercolini, L.; Monti, B.; Bolognesi, M.L. \u03b1-Linolenic acid\u2013valproic acid conjugates: toward single-molecule polypharmacology for multiple sclerosis. ACS Med Chem Lett 2020,11(12),2406-2413","journal-title":"ACS Med Chem Lett"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/1381612023396357","volume":"8","author":"Burgaud J.","year":"2002","unstructured":"Burgaud J.; Riffaud J.; Soldato P.; Nitric-oxide releasing molecules: a new class of drugs with several major indications. Curr Pharm Des 2002,8(3),201-213","journal-title":"Curr Pharm Des"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0928-0987(01)00183-X","volume":"14","author":"Gilmer J.F.","year":"2001","unstructured":"Gilmer J.F.; Moriarty L.M.; McCafferty D.F.; Clancy J.M.; Synthesis, hydrolysis kinetics and anti-platelet effects of isosorbide mononitrate derivatives of aspirin. Eur J Pharm Sci 2001,14(3),221-227","journal-title":"Eur J Pharm Sci"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.2042-7158.2011.01380.x","volume":"64","author":"Harmon S.","year":"2011","unstructured":"Harmon S.; Inkielewicz-Stepniak I.; Jones M.; Ledwidge M.; Santos-Martinez M.J.; Medina C.; Radomski M.W.; Gilmer J.F.; Mechanisms of aggregation inhibition by aspirin and nitrate-aspirin prodrugs in human platelets. J Pharm Pharmacol 2011,64(1),77-89","journal-title":"J Pharm Pharmacol"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1016\/j.bmcl.2007.03.009","volume":"17","author":"Gilmer J.F.","year":"2007","unstructured":"Gilmer J.F.; Moriarty L.M.; Clancy J.M.; Evaluation of nitrate-substituted pseudocholine esters of aspirin as potential nitro-aspirins. Bioorg Med Chem Lett 2007,17(11),3217-3220","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1021\/jm2004514","volume":"54","author":"Lazzarato L.","year":"2011","unstructured":"Lazzarato L.; Chegaev K.; Marini E.; Rolando B.; Borretto E.; Guglielmo S.; Joseph S.; Di Stilo A.; Fruttero R.; Gasco A.; New nitric oxide or hydrogen sulfide releasing aspirins. J Med Chem 2011,54(15),5478-5484","journal-title":"J Med Chem"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"804659","DOI":"10.1155\/2015\/804659","volume":"2015","author":"Chiazza F.","year":"2015","unstructured":"Chiazza F.; Chegaev K.; Rogazzo M.; Cutrin J.C.; Benetti E.; Lazzarato L.; Fruttero R.; Collino M.; A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia\/reperfusion. Oxid Med Cell Longev 2015,2015,804659","journal-title":"Oxid Med Cell Longev"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.bmc.2011.11.065","volume":"20","author":"Rolando B.","year":"2012","unstructured":"Rolando B.; Filieri A.; Chegaev K.; Lazzarato L.; Giorgis M.; De Nardi C.; Fruttero R.; Martel S.; Carrupt P.A.; Gasco A.; Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs. Bioorg Med Chem 2012,20(2),841-850","journal-title":"Bioorg Med Chem"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"9057","DOI":"10.1002\/anie.201202414","volume":"51","author":"Barraud N.","year":"2012","unstructured":"Barraud N.; Kardak B.G.; Yepuri N.R.; Howlin R.P.; Webb J.S.; Faust S.N.; Kjelleberg S.; Rice S.A.; Kelso M.J.; Cephalosporin-3\u2032-diazeniumdiolates: targeted NO-donor prodrugs for dispersing bacterial biofilms. Angew Chem Int Ed 2012,51(36),9057-9060","journal-title":"Angew Chem Int Ed"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1021\/jm061371e","volume":"50","author":"Hulsman N.","year":"2007","unstructured":"Hulsman N.; Medema J.P.; Bos C.; Jongejan A.; Leurs R.; Smit M.J.; de Esch I.J.P.; Richel D.; Wijtmans M.; Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J Med Chem 2007,50(10),2424-2431","journal-title":"J Med Chem"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.1021\/jm049681p","volume":"47","author":"Breschi M.C.","year":"2004","unstructured":"Breschi M.C.; Calderone V.; Digiacomo M.; Martelli A.; Martinotti E.; Minutolo F.; Rapposelli S.; Balsamo A.; NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs. J Med Chem 2004,47(23),5597-5600","journal-title":"J Med Chem"},{"key":"ref=230","first-page":"853","volume":"2","author":"Spadaro A.","year":"2010","unstructured":"Spadaro A.; Ronsisvalle G.; Pappalardo M.; Design, synthesis and antiinflammatory activity of novel \u03b3-tocopherol acetylsalicylic acid ester codrug. J Pharm Sci Res 2010,2(12),853-860","journal-title":"J Pharm Sci Res"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/S0968-0896(00)00100-0","volume":"8","author":"Carvalho E.","year":"2000","unstructured":"Carvalho E.; Francisco A.P.; Iley J.; Rosa E.; Triazene drug metabolites. Part 17: synthesis and plasma hydrolysis of acyloxymethyl carbamate derivatives of antitumour triazenes. Bioorg Med Chem 2000,8(7),1719-1725","journal-title":"Bioorg Med Chem"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"6494","DOI":"10.1021\/acs.jmedchem.5b00536","volume":"58","author":"Zhu Y.","year":"2015","unstructured":"Zhu Y.; Fu J.; Shurlknight K.L.; Soroka D.N.; Hu Y.; Chen X.; Sang S.; Novel resveratrol-based aspirin prodrugs: synthesis, metabolism, and anticancer activity. J Med Chem 2015,58(16),6494-6506","journal-title":"J Med Chem"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/17518253.2012.657251","volume":"5","author":"Kankanala K.","year":"2012","unstructured":"Kankanala K.; Billur R.; Reddy V.R.; Mukkanti K.; Pal S.; TFAA-H3 PO4 mediated rapid and single-step synthesis of mutual prodrugs of paracetamol and NSAIDs. Green Chem Lett Rev 2012,5(3),421-432","journal-title":"Green Chem Lett Rev"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"29","DOI":"10.53879\/id.49.10.p0025","volume":"49","author":"Visagaperumal D.","year":"2012","unstructured":"Visagaperumal D.; Mayuren C.; Anbalagan N.; Varma R.P.; Srinivas B.; Shanker Bontha V.B.; Ravikumar G.; A facile synthesis of mutual prodrug of diclofenac sodium and paracetamol and its preformulation studies. Indian Drugs 2012,49(10),29","journal-title":"Indian Drugs"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"1894907","DOI":"10.1155\/2020\/1894907","volume":"2020","author":"Assali M.","year":"2020","unstructured":"Assali M.; Abualhasan M.; Zohud N.; Ghazal N.; RP-HPLC Method development and validation of synthesized codrug in combination with indomethacin, paracetamol, and famotidine. Int J Anal Chem 2020,2020,1894907","journal-title":"Int J Anal Chem"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1007\/s00044-011-9589-1","volume":"21","author":"Sawraj S.","year":"2012","unstructured":"Sawraj S.; Bhardawaj T.R.; Sharma P.D.; Design, synthesis, and evaluation of novel indomethacin\u2013antioxidant codrugs as gastrosparing NSAIDs. Med Chem Res 2012,21(6),834-843","journal-title":"Med Chem Res"},{"key":"ref=237","first-page":"1426","volume":"9","author":"Avhad D.M.","year":"2020","unstructured":"Avhad D.M.; Chaple D.R.; Asnani A.J.; Mohurle S.; Pratyush K.; Tale R.R.; Synthesis and evaluation of mutual prodrugs of ibuprofen as non steroidal anti-inflammatory drugs with antioxidants. World J Pharm Pharm Sci 2020,9(5),1426-1438","journal-title":"World J Pharm Pharm Sci"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1159\/000346445","volume":"59","author":"Zara S.","year":"2013","unstructured":"Zara S.; De Colli M.; Rapino M.; Pacella S.; Nasuti C.; Sozio P.; Di Stefano A.; Cataldi A.; Ibuprofen and lipoic acid conjugate neuroprotective activity is mediated by Ngb\/Akt intracellular signaling pathway in Alzheimer\u2019s disease rat model. Gerontology 2013,59(3),250-260","journal-title":"Gerontology"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"105856","DOI":"10.1016\/j.intimp.2019.105856","volume":"76","author":"de Oliveira Pedrosa Rolim M.","year":"2019","unstructured":"de Oliveira Pedrosa Rolim M.; de Almeida A.R.; da Rocha Pitta M.G.; de Melo R\u00eago M.J.B.; Quintans-J\u00fanior L.J.; de Souza Siqueira Quintans J.; Heimfarth L.; Scotti L.; Scotti M.T.; da Cruz R.M.D.; de Almeida R.N.; da Silva T.G.; de Oliveira J.A.; de Campos M.L.; Marchand P.; Mendon\u00e7a-Junior F.J.B.; Design, synthesis and pharmacological evaluation of CVIB, a codrug of carvacrol and ibuprofen as a novel anti-inflammatory agent. Int Immunopharmacol 2019,76,105856","journal-title":"Int Immunopharmacol"},{"key":"ref=240","first-page":"158","volume":"66","author":"Bhosale A.V.","year":"2004","unstructured":"Bhosale A.V.; Agarwal G.P.; Mishra P.; Preparation and characterization of mutual prodrugs of ibuprofen. Indian J Pharm Sci 2004,66,158-163","journal-title":"Indian J Pharm Sci"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11094-014-1089-4","volume":"48","author":"Shah K.","year":"2014","unstructured":"Shah K.; Shrivastava S.K.; Mishra P.; Synthesis, kinetics and pharmacological comparison of a mutual prodrug of mefenamic acid to related physical mixture. Pharm Chem J 2014,48(4),253-259","journal-title":"Pharm Chem J"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0039-128X(89)90054-8","volume":"54","author":"McLean H.M.","year":"1989","unstructured":"McLean H.M.; Lee H.J.; Synthesis and pharmacological evaluation of conjugates of prednisolone and non-steroidal anti-inflammatory agents. Steroids 1989,54(4),421-439","journal-title":"Steroids"},{"key":"ref=243","first-page":"128","volume":"40","author":"Al-Khafaji T.","year":"2021","unstructured":"Al-Khafaji T.; Al-Obaidi Z.M.J.; Alkhafaji S.L.; Molecular docking studies and evaluation of the anti-inflammatory activity of ibuprofen-tranexamic acid codrug. Lat Am J Pharm 2021,40,128-134","journal-title":"Lat Am J Pharm"},{"key":"ref=244","doi-asserted-by":"publisher","first-page":"226","DOI":"10.25258\/ijddt.9.2.18","volume":"9","author":"Al-Obaidi Z.M.J.","year":"2019","unstructured":"Al-Obaidi Z.M.J.; Ali A.A.; Mousa T.H.; Synthesis of novel ibuprofen-tranexamic acid codrug: estimation of the clinical activity against HCT116 colorectal carcinoma cell line and the determination of toxicity profile against MDCK normal kidney cell line. Int J Drug Deliv Technol 2019,9,226-235","journal-title":"Int J Drug Deliv Technol"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1016\/j.bmc.2009.03.065","volume":"17","author":"Abdel-Azeem A.Z.","year":"2009","unstructured":"Abdel-Azeem A.Z.; Abdel-Hafez A.A.; El-Karamany G.S.; Farag H.H.; Chlorzoxazone esters of some non-steroidal anti-inflammatory (NSAI) carboxylic acids as mutual prodrugs: Design, synthesis, pharmacological investigations and docking studies. Bioorg Med Chem 2009,17(10),3665-3670","journal-title":"Bioorg Med Chem"},{"key":"ref=246","first-page":"8","volume":"4","author":"Shaheed D.Q.","year":"2015","unstructured":"Shaheed D.Q.; Hussein A.K.; Mubarak H.; Jassim A.A.K.; Abbas K.; Alrekabi M.D.; Hussein A.H.; Alkhefaji D.Q.S.; Design and synthesis of diclofenac and indomethacin conjugates with gemcitabine as a possible mutual prodrugs. World J Pharm Res 2015,4,8-17","journal-title":"World J Pharm Res"},{"key":"ref=247","doi-asserted-by":"publisher","first-page":"315","DOI":"10.31838\/srp.2020.11.46","volume":"11","author":"Alibeg A.A.A.","year":"2020","unstructured":"Alibeg A.A.A.; Abdulsada A.H.; Nasser N.H.; Ali Beg K.A.A.; Design and synthesis of possible mutual prodrugs of (nsaid) etodolac and tolmetin with (cytotoxic) gemcitabine. Syst Rev Pharm 2020,11(11),315-318","journal-title":"Syst Rev Pharm"},{"key":"ref=248","first-page":"1","volume":"03","author":"Mahdi M.F.","year":"2012","unstructured":"Mahdi M.F.; Razzak N.A.A.; Omer T.N.A.; Hadi M.K.; Design and synthesis of possible mutual prodrugs by coupling of nsaids with sulfa drugs by using glycolic acid as spacer. Int J Compr Pharm 2012,03(02),1-4","journal-title":"Int J Compr Pharm"},{"key":"ref=249","first-page":"241","volume":"2","author":"Qasir A.J.","year":"2013","unstructured":"Qasir A.J.; Synthesis of NSAID with sulfonamide conjugates as possible mutual prodrugs using amino acid spacer. Der Pharma Chem 2013,2(1),241-248","journal-title":"Der Pharma Chem"},{"key":"ref=250","first-page":"508","volume":"2","author":"Nazeruddin G.M.","year":"2010","unstructured":"Nazeruddin G.M.; Suryawanshi S.B.; Synthesis of Novel Mutual Pro-drugs by coupling of Ibuprofen (NSAID) with Sulfa drugs. J Chem Pharm Res 2010,2(4),508-512","journal-title":"J Chem Pharm Res"},{"key":"ref=251","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.bmc.2019.01.012","volume":"27","author":"Asghar A.","year":"2019","unstructured":"Asghar A.; Yousuf M.; Mubeen H.; Nazir R.; Haruna K.; Onawole A.T.; Rasheed L.; Synthesis, spectroscopic characterization, molecular docking and theoretical studies (DFT) of N-(4-aminophenylsulfonyl)-2-(4-isobutylphenyl) propanamide having potential enzyme inhibition applications. Bioorg Med Chem 2019,27(12),2397-2404","journal-title":"Bioorg Med Chem"},{"key":"ref=252","doi-asserted-by":"publisher","first-page":"195","DOI":"10.14233\/ajchem.2018.20981","volume":"30","author":"Naser N.H.","year":"2018","unstructured":"Naser N.H.; Design, synthesis and hydrolysis study of gatifloxacin-NSAIDs as mutual prodrugs. Asian J Chem 2018,30(1),195-200","journal-title":"Asian J Chem"},{"key":"ref=253","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1021\/acs.jmedchem.6b01607","volume":"60","author":"Bua S.","year":"2017","unstructured":"Bua S.; Di Cesare Mannelli L.; Vullo D.; Ghelardini C.; Bartolucci G.; Scozzafava A.; Supuran C.T.; Carta F.; Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs\u2013CAIs) for the treatment of rheumatoid arthritis. J Med Chem 2017,60(3),1159-1170","journal-title":"J Med Chem"},{"key":"ref=254","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3390\/ph5101080","volume":"5","author":"Mahdi M.","year":"2012","unstructured":"Mahdi M.; Alsaad H.; Design, synthesis and hydrolytic behavior of mutual prodrugs of NSAIDs with gabapentin using glycol spacers. Pharmaceuticals (Basel) 2012,5(10),1080-1091","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=255","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0928-0987(02)00159-8","volume":"17","author":"Sheha M.","year":"2002","unstructured":"Sheha M.; Khedr A.; Elsherief H.; Biological and metabolic study of naproxen\u2013propyphenazone mutual prodrug. Eur J Pharm Sci 2002,17(3),121-130","journal-title":"Eur J Pharm Sci"},{"key":"ref=256","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2174\/1567201814666170213153509","volume":"14","author":"Paliwal M.","year":"2017","unstructured":"Paliwal M.; Sucheta R.; Jain S.; Monika H.; Synthesis and biological evaluation of mutual prodrugs of carboxylic group containing some non-steroidal anti-inflammatory drugs and propyphenazone. Curr Drug Deliv 2017,14(8),1213-1224","journal-title":"Curr Drug Deliv"},{"key":"ref=257","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1021\/ml500156v","volume":"5","author":"Radwan M.F.","year":"2014","unstructured":"Radwan M.F.; Dalby K.N.; Kaoud T.S.; Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors. ACS Med Chem Lett 2014,5(9),983-988","journal-title":"ACS Med Chem Lett"},{"key":"ref=258","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00044-010-9363-9","volume":"20","author":"Sawraj S.","year":"2011","unstructured":"Sawraj S.; Bhardawaj T.R.; Sharma P.D.; Design, synthesis and evaluation of novel indomethacin\u2013flavonoid mutual prodrugs as safer NSAIDs. Med Chem Res 2011,20(6),687-694","journal-title":"Med Chem Res"},{"key":"ref=259","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s13346-017-0420-5","volume":"7","author":"Poorvashree J.","year":"2017","unstructured":"Poorvashree J.; Suneela D.; Novel drug delivery of dual acting prodrugs of hydroxychloroquine with aryl acetic acid NSAIDs: Design, kinetics and pharmacological study. Drug Deliv Transl Res 2017,7(5),709-730","journal-title":"Drug Deliv Transl Res"},{"key":"ref=260","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/1871528114666151201200157","volume":"14","author":"Kashmira P.","year":"2015","unstructured":"Kashmira P.; Dhaneshwar S.; Shakuntala C.; Poorvashree J.; Design, synthesis and in vitro release studies of co-drugs for rheumatoid arthritis. Inflamm Allergy Drug Targets 2015,14(1),47-52","journal-title":"Inflamm Allergy Drug Targets"},{"key":"ref=261","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jtumed.2016.03.003","volume":"11","author":"Husain A.","year":"2016","unstructured":"Husain A.; Ahmad A.; Khan S.A.; Synthesis and biological evaluation of a mutual prodrug of norfloxacin and fenbufen. J Taibah Univ Med Sci 2016,11(3),277-281","journal-title":"J Taibah Univ Med Sci"},{"key":"ref=262","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1007\/s11095-010-0274-8","volume":"27","author":"Lau W.M.","year":"2010","unstructured":"Lau W.M.; White A.W.; Heard C.M.; Topical delivery of a naproxen-dithranol co-drug: in vitro skin penetration, permeation, and staining. Pharm Res 2010,27(12),2734-2742","journal-title":"Pharm Res"},{"key":"ref=263","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ajps.2015.10.031","volume":"11","author":"Bhatia N.","year":"2016","unstructured":"Bhatia N.; Katkar K.; Ashtekar S.; Formulation and evaluation of co-prodrug of flurbiprofen and methocarbamol. Asian J Pharmaceut Sci 2016,11(3),449-458","journal-title":"Asian J Pharmaceut Sci"},{"key":"ref=264","first-page":"1882","volume":"6","author":"Chhajed S.","year":"2008","unstructured":"Chhajed S.; Puranik M.; Padwal M.; Deshmukh Z.; Agarwal S.; Yeole P.; Hydrolysis kinetic studies of mutual prodrugs of diclofenac sodium. Int J Chem Sci 2008,6(4),1882-1890","journal-title":"Int J Chem Sci"},{"key":"ref=265","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00044-013-0696-z","volume":"23","author":"Husain A.","year":"2014","unstructured":"Husain A.; Ahuja P.; Shaharyar M.; Ahmad A.; Mkhalid I.A.I.; Alam M.M.; Akhter M.; Zaman M.S.; Synthesis, biological activities, and pharmacokinetics studies of a mutual prodrug of aceclofenac and paracetamol. Med Chem Res 2014,23(3),1077-1083","journal-title":"Med Chem Res"},{"key":"ref=266","first-page":"905","volume":"70","author":"Shah K.","year":"2013","unstructured":"Shah K.; Shrivastava S.K.; Mishra P.; Synthesis, kinetics and pharmacological evaluation of mefenamic acid mutual prodrug. Acta Pol Pharm 2013,70(5),905-911","journal-title":"Acta Pol Pharm"},{"key":"ref=267","first-page":"1279","volume":"48","author":"Manon B.","year":"2009","unstructured":"Manon B.; Sharma P.D.; Design, synthesis and evaluation of diclofenac-antioxidant mutual prodrugs as safer NSAIDs. Indian J. Chem. - Sect. B Org. Med Chem 2009,48(9),1279-1287","journal-title":"Med Chem"},{"key":"ref=268","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1021\/acs.jmedchem.8b00420","volume":"61","author":"Akgul O.","year":"2018","unstructured":"Akgul O.; Di Cesare Mannelli L.; Vullo D.; Angeli A.; Ghelardini C.; Bartolucci G.; Alfawaz Altamimi A.S.; Scozzafava A.; Supuran C.T.; Carta F.; Discovery of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs\u2013CAIs) for the management of rheumatoid arthritis. J Med Chem 2018,61(11),4961-4977","journal-title":"J Med Chem"},{"key":"ref=269","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14805\/jphchem.2017.art69","volume":"4","author":"Redasani V.K.","year":"2017","unstructured":"Redasani V.K.; Bhalerao O.C.; Kalaskar M.G.; Surana S.J.; Synthesis and evaluation of novel mutual prodrugs of Piroxicam. J Pharmaceut Chem 2017,4(1),1-4","journal-title":"J Pharmaceut Chem"},{"key":"ref=270","doi-asserted-by":"publisher","first-page":"27","DOI":"10.31080\/ASPS.2019.03.0305","volume":"3","author":"Imran M.","year":"2019","unstructured":"Imran M.; Asif M.; Mutual prodrugs of piroxicam. Acta Sci Pharmaceut Sci 2019,3(7),27-28","journal-title":"Acta Sci Pharmaceut Sci"},{"key":"ref=271","doi-asserted-by":"publisher","first-page":"336","DOI":"10.46624\/ajptr.2018.v8.i1.024","volume":"8","author":"Aziz Alibeg A.A.","year":"2018","unstructured":"Aziz Alibeg A.A.; Synthesis of mutual pro-drugs through coupling of etodolac and tolmetin by sulfa drugs. Am J Pharm Tech Res 2018,8(1),336-342","journal-title":"Am J Pharm Tech Res"},{"key":"ref=272","doi-asserted-by":"publisher","first-page":"105101","DOI":"10.1016\/j.ejps.2019.105101","volume":"140","author":"Hassib S.T.","year":"2019","unstructured":"Hassib S.T.; Hassan G.S.; El-Zaher A.A.; Fouad M.A.; Abd El-Ghafar O.A.; Taha E.A.; Synthesis and biological evaluation of new prodrugs of etodolac and tolfenamic acid with reduced ulcerogenic potential. Eur J Pharm Sci 2019,140,105101","journal-title":"Eur J Pharm Sci"},{"key":"ref=273","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1016\/S0960-894X(03)00718-2","volume":"13","author":"Kamal A.","year":"2003","unstructured":"Kamal A.; Srinivas O.; Ramulu P.; Ramesh G.; Kumar P.P.; Synthesis of novel C2 and C2\u2013C8 linked pyrrolo[2,1- c][1,4]benzodiazepine-naphthalimide hybrids as DNA-binding agents. Bioorg Med Chem Lett 2003,13(20),3577-3581","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=274","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.bmcl.2004.02.094","volume":"14","author":"Hong-Ju Y.","year":"2004","unstructured":"Hong-Ju Y.; He L.; Wei-Guo S.; Nan Z.; Wei-Xiu Y.; Zhong-Wei J.; Jun-Wei W.; Zheng-Hua G.; Bo-Hua Z.; Zhi-Pu L.; Zhe-Hui G.; Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury. Bioorg Med Chem Lett 2004,14(10),2537-2541","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=275","first-page":"858","volume":"12","author":"Mohammed Z.B.","year":"2021","unstructured":"Mohammed Z.B.; Omar T.N.; Chemical design, synthesis and biological evaluation of mutual prodrug of gabapentin with different types of phenolic and alcoholic antioxidants. Syst Rev Pharm 2021,12(1),858-868","journal-title":"Syst Rev Pharm"},{"key":"ref=276","first-page":"98","author":"Dhooper H. K.","year":"2010","unstructured":"Dhooper H. K.; Opioid-cannabinoid codrugs with enhanced analgesic and pharmacokinetic profile, University of Kentucky Doctoral Dissertations. 2010,98"},{"key":"ref=277","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1021\/jm010980d","volume":"45","author":"Huuskonen J.","year":"2002","unstructured":"Huuskonen J.; Nevalainen T.; Gynther J.; Taipale H.; Ja T.; Design and synthesis of a novel L-dopa-entacapone codrug. J Med Chem 2002,45(6),1379-1382","journal-title":"J Med Chem"},{"key":"ref=278","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijpharm.2012.08.023","volume":"437","author":"Denora N.","year":"2012","unstructured":"Denora N.; Cassano T.; Laquintana V.; Lopalco A.; Trapani A.; Cimmino C.S.; Laconca L.; Giuffrida A.; Trapani G.; Novel codrugs with GABAergic activity for dopamine delivery in the brain. Int J Pharm 2012,437(1-2),221-231","journal-title":"Int J Pharm"},{"key":"ref=279","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1021\/jm070037v","volume":"50","author":"Pinnen F.","year":"2007","unstructured":"Pinnen F.; Cacciatore I.; Cornacchia C.; Sozio P.; Iannitelli A.; Costa M.; Pecci L.; Nasuti C.; Cantalamessa F.; Di Stefano A.; Synthesis and study of L-dopa-glutathione codrugs as new anti-Parkinson agents with free radical scavenging properties. J Med Chem 2007,50(10),2506-2515","journal-title":"J Med Chem"},{"key":"ref=280","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3390\/antiox8080319","volume":"8","author":"Franceschelli S.","year":"2019","unstructured":"Franceschelli S.; Lanuti P.; Ferrone A.; Gatta D.M.P.; Speranza L.; Pesce M.; Grilli A.; Cacciatore I.; Ricciotti E.; Di Stefano A.; Miscia S.; Felaco M.; Patruno A.; Modulation of apoptotic cell death and neuroprotective effects of glutathione\u2014L-Dopa codrug against H2O2-induced cellular toxicity. Antioxidants 2019,8(8),319","journal-title":"Antioxidants"},{"key":"ref=281","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1021\/jm800239v","volume":"51","author":"More S.S.","year":"2008","unstructured":"More S.S.; Vince R.; Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs. J Med Chem 2008,51(15),4581-4588","journal-title":"J Med Chem"},{"key":"ref=282","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1021\/jm801266x","volume":"52","author":"Pinnen F.","year":"2009","unstructured":"Pinnen F.; Cacciatore I.; Cornacchia C.; Sozio P.; Cerasa L.S.; Iannitelli A.; Nasuti C.; Cantalamessa F.; Sekar D.; Gabbianelli R.; Falcioni M.L.; Stefano A.D.; Codrugs linking L-dopa and sulfur-containing antioxidants: new pharmacological tools against Parkinson\u2019s disease. J Med Chem 2009,52(2),559-563","journal-title":"J Med Chem"},{"key":"ref=283","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/ardp.200700228","volume":"341","author":"Sozio P.","year":"2008","unstructured":"Sozio P.; Iannitelli A.; Cerasa L.S.; Cacciatore I.; Cornacchia C.; Giorgioni G.; Ricciutelli M.; Nasuti C.; Cantalamessa F.; Di Stefano A.; New L-dopa codrugs as potential antiparkinson agents. Arch Pharm (Weinheim) 2008,341(7),412-417","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=284","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1021\/jm00221a014","volume":"20","author":"Bodor N.","year":"1977","unstructured":"Bodor N.; Sloan K.B.; Higuchi T.; Sasahara K.; Improved delivery through biological membranes. 4. Prodrugs of L-DOPA. J Med Chem 1977,20(11),1435-1445","journal-title":"J Med Chem"},{"key":"ref=285","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0161-813X(02)00035-9","volume":"23","author":"Bharath S.","year":"2002","unstructured":"Bharath S.; Cochran B.C.; Hsu M.; Liu J.; Ames B.N.; Andersen J.K.; Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson\u2019s disease therapy. Neurotoxicology 2002,23(4-5),479-486","journal-title":"Neurotoxicology"},{"key":"ref=286","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2174\/157018006778631947","volume":"3","author":"Di Stefano A.","year":"2006","unstructured":"Di Stefano A.; Sozio P.; Iannitelli A.; Cocco A.; Orlando G.; Ricciutelli M.; Synthesis and preliminary evaluation of L-dopa\/benserazide conjugates as dual acting codrugs. Lett Drug Des Discov 2006,3(10),747-752","journal-title":"Lett Drug Des Discov"},{"key":"ref=287","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00726-010-0804-z","volume":"42","author":"Pinnen F.","year":"2012","unstructured":"Pinnen F.; Cacciatore I.; Cornacchia C.; Mollica A.; Sozio P.; Cerasa L.S.; Iannitelli A.; Fontana A.; Nasuti C.; Di Stefano A.; CNS delivery of l-dopa by a new hybrid glutathione\u2013methionine peptidomimetic prodrug. Amino Acids 2012,42(1),261-269","journal-title":"Amino Acids"},{"key":"ref=288","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1021\/acs.molpharmaceut.7b00405","volume":"14","author":"Cassano T.","year":"2017","unstructured":"Cassano T.; Lopalco A.; de Candia M.; Laquintana V.; Lopedota A.; Cutrignelli A.; Perrone M.; Iacobazzi R.M.; Bedse G.; Franco M.; Denora N.; Altomare C.D.; Oxazepam\u2013dopamine conjugates increase dopamine delivery into striatum of intact rats. Mol Pharm 2017,14(9),3178-3187","journal-title":"Mol Pharm"},{"key":"ref=289","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1021\/mp200327k","volume":"8","author":"Lau W.M.","year":"2011","unstructured":"Lau W.M.; Ng K.W.; White A.W.; Heard C.M.; Therapeutic and cytotoxic effects of the novel antipsoriasis codrug, naproxyl-dithranol, on HaCaT cells. Mol Pharm 2011,8(6),2398-2407","journal-title":"Mol Pharm"},{"key":"ref=290","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11095-004-9008-0","volume":"22","author":"Ben-Shabat S.","year":"2005","unstructured":"Ben-Shabat S.; Benisty R.; Wormser U.; Sintov A.C.; Vitamin D3-based conjugates for topical treatment of psoriasis: synthesis, antiproliferative activity, and cutaneous penetration studies. Pharm Res 2005,22(1),50-57","journal-title":"Pharm Res"},{"key":"ref=291","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1021\/bc200645n","volume":"23","author":"Dao K.L.","year":"2012","unstructured":"Dao K.L.; Sawant R.R.; Hendricks J.A.; Ronga V.; Torchilin V.P.; Hanson R.N.; Design, synthesis, and initial biological evaluation of a steroidal anti-estrogen-doxorubicin bioconjugate for targeting estrogen receptor-positive breast cancer cells. Bioconjug Chem 2012,23(4),785-795","journal-title":"Bioconjug Chem"},{"key":"ref=292","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1021\/ja017344p","volume":"124","author":"Mitra K.","year":"2002","unstructured":"Mitra K.; Marquis J.C.; Hillier S.M.; Rye P.T.; Zayas B.; Lee A.S.; Essigmann J.M.; Croy R.G.; A rationally designed genotoxin that selectively destroys estrogen receptor-positive breast cancer cells. J Am Chem Soc 2002,124(9),1862-1863","journal-title":"J Am Chem Soc"},{"key":"ref=293","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1016\/j.bmcl.2004.04.064","volume":"14","author":"Sharma U.","year":"2004","unstructured":"Sharma U.; Marquis J.C.; Nicole Dinaut A.; Hillier S.M.; Fedeles B.; Rye P.T.; Essigmann J.M.; Croy R.G.; Design, synthesis, and evaluation of estradiol-linked genotoxicants as anti-cancer agents. Bioorg Med Chem Lett 2004,14(14),3829-3833","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=294","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1021\/jo0055842","volume":"66","author":"Jones G.B.","year":"2001","unstructured":"Jones G.B.; Hynd G.; Wright J.M.; Purohit A.; Plourde G.W.; Huber R.S.; Mathews J.E.; Li A.; Kilgore M.W.; Bubley G.J.; Yancisin M.; Brown M.A.; Target-directed enediynes: designed estramycins. J Org Chem 2001,66(11),3688-3695","journal-title":"J Org Chem"},{"key":"ref=295","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1021\/jm9602930","volume":"39","author":"Devraj R.","year":"1996","unstructured":"Devraj R.; Barrett J.F.; Fernandez J.A.; Katzenellenbogen J.A.; Cushman M.; Design, synthesis, and biological evaluation of ellipticine - estradiol conjugates. J Med Chem 1996,39,3367-3374","journal-title":"J Med Chem"},{"key":"ref=296","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1016\/j.bmcl.2014.09.079","volume":"24","author":"Dang Thi T.A.","year":"2014","unstructured":"Dang Thi T.A.; Kim Tuyet N.T.; Pham The, C.; Thanh Nguyen, H.; Ba Thi, C.; Doan Duy, T.; D\u2019hooghe, M.; Van Nguyen, T. Synthesis and cytotoxic evaluation of novel ester-triazole-linked triterpenoid\u2013AZT conjugates. Bioorg Med Chem Lett 2014,24(22),5190-5194","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=297","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.1016\/j.bmc.2009.07.050","volume":"17","author":"Santos R.C.","year":"2009","unstructured":"Santos R.C.; Salvador J.A.R.; Mar\u00edn S.; Cascante M.; Novel semisynthetic derivatives of betulin and betulinic acid with cytotoxic activity. Bioorg Med Chem 2009,17(17),6241-6250","journal-title":"Bioorg Med Chem"},{"key":"ref=298","doi-asserted-by":"publisher","first-page":"7762","DOI":"10.1038\/srep07762","volume":"5","author":"Saha S.","year":"2015","unstructured":"Saha S.; Ghosh M.; Dutta S.K.; A potent tumoricidal co-drug \u2018Bet-CA\u2019 - an ester derivative of betulinic acid and dichloroacetate selectively and synergistically kills cancer cells. Sci Rep 2015,5(1),7762","journal-title":"Sci Rep"},{"key":"ref=299","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1021\/jm100404t","volume":"53","author":"Horwedel C.","year":"2010","unstructured":"Horwedel C.; Tsogoeva S.B.; Wei S.; Efferth T.; Cytotoxicity of artesunic acid homo- and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells. J Med Chem 2010,53(13),4842-4848","journal-title":"J Med Chem"},{"key":"ref=300","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.ejmech.2014.01.031","volume":"75","author":"Emmerich D.","year":"2014","unstructured":"Emmerich D.; Vanchanagiri K.; Baratto L.C.; Schmidt H.; Paschke R.; Synthesis and studies of anticancer properties of lupane-type triterpenoid derivatives containing a cisplatin fragment. Eur J Med Chem 2014,75,460-466","journal-title":"Eur J Med Chem"},{"key":"ref=301","doi-asserted-by":"publisher","first-page":"7582","DOI":"10.1016\/j.bmcl.2012.10.017","volume":"22","author":"Suneela D.","year":"2012","unstructured":"Suneela D.; Dipmala P.; Synthesis and pharmacokinetic profile of rhein- boswellic acid conjugate. Bioorg Med Chem Lett 2012,22(24),7582-7587","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=302","doi-asserted-by":"publisher","first-page":"10973","DOI":"10.1021\/acs.jafc.7b04378","volume":"65","author":"Zheng G.","year":"2017","unstructured":"Zheng G.; Shen Z.; Xu A.; Jiang K.; Wu P.; Yang X.; Chen X.; Shao J.; Synergistic chemopreventive and therapeutic effects of co-drug ua-met: Implication in tumor metastasis. J Agric Food Chem 2017,65(50),10973-10983","journal-title":"J Agric Food Chem"},{"key":"ref=303","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejps.2011.10.028","volume":"45","author":"Zhong Y.","year":"2012","unstructured":"Zhong Y.; Dai Z.; Xu Y.; Teng Y.; Wu B.; Synthesis, stability and pharmacological evaluation of a novel codrug consisting of lamivudine and ursolic acid. Eur J Pharm Sci 2012,45(1-2),110-115","journal-title":"Eur J Pharm Sci"},{"key":"ref=304","doi-asserted-by":"publisher","first-page":"e86724","DOI":"10.1371\/journal.pone.0086724","volume":"9","author":"Li S.","year":"2014","unstructured":"Li S.; Meng F.; Liao X.; Wang Y.; Sun Z.; Guo F.; Li X.; Meng M.; Li Y.; Sun C.; Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats. PLoS One 2014,9(1),e86724","journal-title":"PLoS One"},{"key":"ref=305","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/jlcr.3434","volume":"59","author":"Motaleb M.A.","year":"2016","unstructured":"Motaleb M.A.; Abo-kul M.; Ibrahim S.M.; Saad S.M.; Arafat M.; Synthesis of 125I-lamivudine and 125I-lamivudine-ursodeoxycholic acid codrug. J Labelled Comp Radiopharm 2016,59(11),451-453","journal-title":"J Labelled Comp Radiopharm"},{"key":"ref=306","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bioorg.2013.06.007","volume":"49","author":"Jain A.K.","year":"2013","unstructured":"Jain A.K.; Gund M.G.; Desai D.C.; Borhade N.; Senthilkumar S.P.; Dhiman M.; Mangu N.K.; Mali S.V.; Dubash N.P.; Halder S.; Satyam A.; Mutual prodrugs containing bio-cleavable and drug releasable disulfide linkers. Bioorg Chem 2013,49,40-48","journal-title":"Bioorg Chem"},{"key":"ref=307","doi-asserted-by":"publisher","first-page":"193","DOI":"10.18388\/abp.2011_2264","volume":"58","year":"2011","unstructured":"Lovri\u0107 J.; Berend, S.; Luci\u0107 Vrdoljak, A.; Radi\u0107 B.; Katalini\u0107 M.; Kovarik, Z.; \u017delje\u017ei\u0107 D.; Kopjar, N.; Rast, S.; Mesi\u0107 M. A conjugate of pyridine-4-aldoxime and atropine as a potential antidote against organophosphorus compounds poisoning. Acta Biochim Pol 2011,58(2),193-198","journal-title":"Acta Biochim Pol"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666221209102650","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211809\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666221209102650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T20:03:18Z","timestamp":1693684998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211809\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":307,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666221209102650","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}